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Hereditary gelsolin amyloidosis (HGA), also known as AGel amyloidosis and Meretoja disease, 
is a dominantly inherited systemic disease that belongs to the Finnish disease heritage.  HGA 
is mostly found in Finland but nowadays also reported worldwide.  
The disease is caused by a c.640G>A/T point mutation in the GSN gene coding for gelsolin 
which further results in the mutation p.D214N or p.D214Y on the protein level. Due to these 
mutations, variant gelsolin is misfolded and undergoes abnormal enzymatic cleavages by furin 
and matrix metalloproteinase 14 (MMP-14) leading to gelsolin amyloid (AGel) formation. 
Gelsolin is expressed in two forms of which the extracellular one has been indicated to be the 
source for the misfolded form. Gelsolin has several functions of which the most important is 
actin fibril remodeling intra- and extracellularly.  
HGA is characterized mainly by ophthalmological, neurological and dermatological 
manifestations. However, HGA patients can also have cardiovascular, hemorrhagic and 
potentially vascularly induced neurological problems. AGel amyloid fibrils accumulate 
extracellularly at the basal lamina of epithelial and muscle cells and alongside elastic fibres. 
Thus, amyloid angiopathy is encountered in nearly every organ. AGel deposition associates 
with elastic fibre degradation leading to severe clinical manifestations, such as cutis laxa and 
angiopathic complications.   
The aim of this study was to characterise the pathological changes of AGel amyloid angiopathy 
in small arteries, to elucidate pathomechanisms of amyloid related elastolysis, and to 
investigate the effects of variant gelsolin in vascular smooth muscle cells from the HGA 
patients. 
To characterise the pathological changes of AGel amyloid angiopathy, we performed 
histological, immunohistochemical and transmission electron microscopic (TEM) analyses on 
facial temporal artery branches. This study revealed major pathological changes in arteries: 
disruption of the tunica media, disorganization of vascular smooth muscle cells, and 
accumulation of AGel fibrils in arterial walls, where they associate strongly with the lamina 
elastica interna, which becomes fragmented and diminished. We also provide evidence of 
abnormal accumulation and localization of collagen types I and III and an increase of collagen 




To elucidate pathomechanisms of amyloid related elastolysis, we analysed elastic fibre 
pathology in dermal and vascular tissue and plasma samples from HGA patients and control 
subjects by TEM, immunohistochemistry and enzyme-linked immunosorbent assay (ELISA). In 
addition to the morphological examination, we also studied the roles of MMP-2, -7, -9, -12 
and -14, TIMP-1 and TGFβ. We found massive accumulation of amyloid fibrils along elastic 
fibres as well as fragmentation and loss of elastic fibres in all dermal and vascular samples of 
HGA patients. Fibrils of distinct types formed a fibrous matrix. The degradation pattern of 
elastic fibres in HGA patients was different from the age-related degradation in controls. The 
elastin of elastic fibres in HGA patients was also remarkably decreased compared to controls. 
Interestingly, MMP-9 was expressed at lower and TGFβ at higher levels in HGA patients than 
in controls.  
To investigate the effects of gelsolin amyloidosis in vascular smooth muscle cells (VSMCs) we 
established unique cell lines from the HGA patients. As the c.640G>A mutation is located in 
the actin regulatory site of gelsolin, we speculated that this could impair cytosolic functions of 
gelsolin. We therefore conducted cell studies examining actin cytoskeleton morphology, 
cytosolic gelsolin distribution, migration, and collagen type I metabolism in VSMCs. We also 
treated the cells with phorbol 12-myristate 13-acetate (PMA) and staurosporine, regulators 
of protein kinase C, but the HGA patient and control cell lines did not show significant 
differences in any of these study settings. Also, in TEM analyses VSMCs in arteries appeared 
to be morphologically and semi-quantitatively normal, only their basal lamina was often 
thickened. 
According to this study the AGel amyloid angiopathy in HGA results in severe disruption of 
arterial walls, characterized by prominent AGel deposition, collagen derangement and severe 
elastolysis, which may be responsible for several, particularly hemorrhagic, disease 
manifestations in HGA. The accumulation of AGel fibrils with severe elastolysis characterizes 
both dermal and vascular tissues. The unaltered cytoskeletal actin-gelsolin interactions in 
studied cells imply that HGA results rather from a toxic gain-of-function than loss-of-function 
mechanism. Furthermore, we found two potential biomarkers to be used as diagnostic 
markers in evaluating the progression of HGA in patients. The first one, alcohol dehydrogenase 
1B (ADH1B), was found in two-dimensional ultra-performance liquid chromatography with 
tandem mass spectrometry (2D-UPLC-MS/MS) proteomic analyses of VCMSs, and the second 











I have been involved with hereditary gelsolin amyloidosis (HGA) all my life. I was born in 
Kymenlaakso which is one of the areas where HGA is highly represented. The prevalence of 
HGA in Kymenlaakso was estimated in 1970s to be as high as 1:1 040 (Meretoja, 1973). There 
are many families that carry this hereditary disease, including my own.  
Finland has been an optimal environment for development of rare hereditary diseases due to 
the national and regional isolation. HGA is one member of the Finnish disease heritage which 
includes altogether 36 different inherited diseases that are more frequent in Finland than in 
any other population. 
HGA is a systemic amyloidosis that affects many tissues and organs all around the body. In 
amyloidosis proteins or peptides are self-assembling into β-sheets structures which further 
form organized amyloid fibrils. These amyloid fibrils accumulate to different tissues depending 
on the nature of the protein or peptide and other factors that favor fibril formation. The best-
known amyloidosis is Alzheimer’s disease where amyloid is locally deposited in the brain 
causing neurodegeneration and severe dementia. 
HGA is caused by a mutation in the gelsolin protein. Variant gelsolin undergoes an alternative 
proteolytic cleavage leading to AGel amyloid formation. AGel accumulates at the basal lamina 
of many types of epithelial- and muscle cells, as well as peripheral nerves. Deposition of AGel 
is found in arterial walls in nearly every organ, including the nervous system.  
HGA is characterized by ophthalmological, neurological, and dermatological manifestations. 
Although HGA progresses slowly in heterozygous patients it causes many difficulties like dry 
and irritable eyes, loose, itching and dry skin, distal paresthesias and manual clumsiness, 
bilateral facial nerve paresis which can cause severe facial disfigurement, dysarthria and, loss 
of vision, with severely decreased quality of life. As a possible consequence of amyloid 
angiopathy, HGA patients get easily superficial bruises and hematomas, they have commonly 
cardiac diseases and arrhythmias, and the consumption of cardiovascular medication is 
significantly increased. 
I have had a privilege to study HGA both in my masters and doctoral theses. For this study we 




characterize the pathological changes of AGel amyloid angiopathy, elucidate 
pathomechanisms of amyloid related elastolysis and investigate the effects of HGA in vascular 





Review of the literature 
1 Amyloid angiopathy 
Angiopathy is a general term for different diseases of the blood vessels. In this thesis the focus 
is on the angiopathies caused by amyloid accumulation in the vessel walls called either 
amyloid angiopathies or vascular amyloidoses. 
1.1 Amyloid 
In amyloid diseases proteins or peptides are self-assembling into well-organised fibrillar 
aggregates forming β-sheet structures. β-sheets consist of β-strands which are connected and 
stabilized by at least two or three interstrand hydrogen bonds. β-sheet structures are known 
as amyloid or amyloid like fibrils (Sipe, Cohen, 2000). These fibrils are insoluble and cannot be 
digested enzymatically which makes them pathological as they accumulate intracellularly 
and/or in the extracellular spaces of organs and tissues. Amyloid formation is generally caused 
by protein misfolding due to a mutation in the target protein and/or by other surrounding 
factors like pathological chaperons, metal ions (Cu2+, Zn2+ or Fe3+) and/or conditions like 
oxidative stress.  
Chaperons and oxidative stress play a major role in amyloid fibril formation. Often late-onset 
neurodegenerative diseases are developing because chaperons are losing their capacity of 
regulating the protein folding process. There are also specific pathological chaperons like 
glycosaminoglycans (GAGs) (Iannuzzi, Irace & Sirangelo, 2015), serum amyloid P component 
(SAP) (Pepys et al., 1982), apolipoprotein E (ApoE) (Soto et al., 1995, Liu et al., 2017) and 
collagen fibres (Benseny-Cases et al., 2019) which enable and accelerate amyloid fibril 
formation. 
Amyloid is recognized by specific properties, such as green-yellow birefringence under 
polarized light after staining with Congo red dye (Puchtler, Sweat & Levine, 1962, Benson et 
al., 2018). Also, Thioflavin S and T dyes are partially specific for amyloid deposits. Under 
electron microscopy amyloid fibrils appear like disordered non-branching rods but they can 




fibrils are approximately 10 nm in diameter. Isolated amyloid fibrils can be analysed also with 
X-ray where they show the characteristic cross β diffraction pattern (Eanes, Glenner, 1968). 
Different types of amyloid proteins are generally characterised using immunohistochemistry 
where histological tissue samples can be analysed with one or several specific antibodies 
against amyloidogenic proteins or peptides (Linke, 2012).  
1.2 Amyloidoses 
Amyloidoses are a family of diseases characterised by the extracellular and/or intracellular 
deposition and accumulation of amyloid fibrils with concomitant destruction of normal tissue 
structure and function leading to organ dysfunction (Cohen, 1967, LaFerla, Green & Oddo, 
2007). Amyloid fibrils can accumulate e.g. in brain and nerves, heart and blood vessels, kidney, 
liver, spleen, and ocular structures causing different clinical phenotypes like dementia, 
neuropathy, cardiomyopathy, hypertension, hepatomegaly, proteinuria, renal failure, 
macroglossia, autonomic dysfunction, ecchymoses, and corneal and vitreous abnormalities 
(Bustamante, Brito, 2017). More than 30 different proteins causing amyloidosis are known. 
Table 1 shows all fibril proteins reported to date, listed according to the International Society 
of Amyloidosis 2018 Nomenclature Guidelines (Benson et al., 2018).  
Amyloidoses are categorised in to systemic and localised as well as acquired and hereditary 
forms. The most common types of systemic amyloidoses (fibril protein in brackets) are light 
chain amyloidosis (AL), inflammation related serum amyloid A amyloidosis (AA), hemodialysis-
related β2-microglobulin amyloidosis (Aβ2M), and transthyretin amyloidosis (ATTR) whereas 
Alzheimer’s disease (Aβ) is the most common and known type of localised amyloidosis. Less 
than a half of all different amyloidoses known at present are hereditary. These inherited forms 
of amyloidosis are almost always systemic, where protein misfolding due to a mutation in the 
amyloid precursor protein is involved. The term familial amyloidosis is also still in use although 
it is not recommended anymore (Benson et al., 2018). Previously familial amyloidosis was used 
when the syndrome occured in a familial setting due to mutations in genes expressing non-
amyloid proteins, such as in AA amyloidosis, whereas hereditary amyloidosis were used when 
there was a mutation in the fibril protein gene itself, like in e.g. ATTR or AGel (Sipe et al., 2016). 




amyloidoses but these terms are not in use any longer. Globally the incidence of amyloidosis 
is estimated at five to nine cases per million patient-years (Real de Asua et al., 2014). 
 
Table 1. Amyloid fibril proteins and their precursors in humans. Modified after International 
Society of Amyloidosis nomenclature committee (Benson et al., 2018). 
Amyloid angiopathy known to be involved: 
Fibril 
protein Precursor protein 
Systemic and/ or 
localized 
Acquired or 
hereditary Target organs 
ABri ABriPP, variants S H Central nervous system 
ACys Cystatin C, variants S H Peripheral nervous system, skin 
ADan ADanPP, variants L H Central nervous system 
APrP Prion protein, wild type L A Creutzfeldt-Jakob disease, fatal insomnia 
  Prion protein variants L H Creutzfeldt-Jakob disease, Gerstmann-
Sträussler-Scheinker syndrome, fatal 
insomnia 
Prion protein variant S H Peripheral nervous system 
Aβ Aβ protein precursor, wild type L A Central nervous system 
  Aβ protein precursor, variant L H Central nervous system 
AGel Gelsolin, variants S H Peripheral nervous system, cornea, cutis 
laxa 
ATTR Transthyretin, wild type S A Heart mainly in males, ligaments, 
tenosynovium 
Transthyretin, variants S H Peripheral and autonomic nervous 
system, heart, eye, leptomeninges 
AL Immunoglobulin light chain S, L A, H All organs, usually except central nervous 
system 
AH Immunoglobulin heavy chain S, L A All organs except central nervous system 
AA (Apo) Serum amyloid A S A All organs except central nervous system 
Aβ2M β2-Microglobulin, wild type S A Musculoskeletal system 
β2-Microglobulin, variant S H Autonomic nervous system 
AApoAI Apolipoprotein A I, variants S H Heart, liver, kidney, PNS, testis, larynx (C-
terminal variants), skin (C-terminal 
variants) 
ALys Lysozyme, variants S H Kidney 
AANF Atrial natriuretic factor L A Cardiac atria 
AMed Lactadherin L A Senile aortic, media 
 
Amyloid fibril proteins that causes amyloidoses with cerebral amyloid angiopathy (CAA) in bold. 
 




No amyloid angiopathy known to be involved: 






hereditary Target organs 
AApoAII Apolipoprotein A II, variants S H Kidney 
AApoAIV Apolipoprotein A IV, wild type S A Kidney medulla and systemic 
AApoCII Apolipoprotein C II, variants S H Kidney 
AApoCIII Apolipoprotein C III, variants S H Kidney 
ALECT2 Leukocyte chemotactic factor-2 S A Kidney, primarily 
AFib Fibrinogen α, variants S H Kidney, primarily 
AαSyn α-Synuclein L A Central nervous system 
ATau Tau L A Central nervous system 
ACal (Pro)calcitonin L A C-cell thyroid tumors 
AIAPP Islet amyloid polypeptide* L A Islets of Langerhans, 
insulinomas 
APro Prolactin L A Pituitary prolactinomas, aging 
pituitary 
AIns Insulin L A Latrogenic, local injection 
ASPC Lung surfactant protein L A Lung 
AGal7 Galectin 7 L A Skin 
ACor Corneodesmosin L A Cornified epithelia, hair 
follicles 
AKer Kerato-epithelin L A Cornea, hereditary 
ALac Lactoferrin L A Cornea 
AOAAP Odontogenic ameloblast-associated protein L A Odontogenic tumors 
ASem1 Semenogelin 1 L A Vesicula seminalis 
AEnf Enfurvitide L A Latrogenic 
ACatK Cathepsin K L A Tumor associated 
* Also called amylin. 
 
1.3 Vascular system 
The vascular system includes all vessels of the body from the aorta to arteries, capillaries and 
veins. Through this system blood streams to different parts and organs in the body. Arteries 
and their smaller branches called arterioles are the vessels that carry blood away from the 
heart. In the smallest very thin walled vessels, capillaries, all nutrients and wastes are 
exchanged between the blood and body tissues. Capillaries connect the arterioles and 
venules, which enables returning the blood back to the heart though veins. 
1.3.1 Structure of arteries 
The wall of an artery consists of three layers: 1) the tunica intima (the innermost layer), 2) the 




In the tunica intima the inner surface is lined by a smooth endothelium which is separated 
from the external layers of the artery by the basal lamina. In the interface of the tunica intima 
and the tunica media lies a layer of elastic fibres called the lamina elastica interna. The tunica 
media consist of smooth muscle cells, elastic and collagen fibres and other connective tissue 
components. Between the outermost layer, the tunica adventitia, and the tunica media there 
is another layer of elastic fibres, the lamina elastica externa. The tunica adventitia is composed 
entirely of connective tissue components made of collagenous and elastic fibres. In larger 
arteries the tunica externa includes also separate blood vessels called the vasa vasorum that 
supply nutrients to these vessels. The smallest blood vessels, arterioles, which represent 
continuation of arterial branches and lead arterial blood to the capillary bed, have the tunica 
intima but their tunica media may contain only a single layer of smooth muscle cells and lack 
elastic fibres.  
Collagen is extracellular insoluble polymeric protein (Bailey, 1978). Out of 28 different 
collagen types, collagen type I and III are major constituents of the tunica intima, tunica media 
and tunica adventitia. Also collagen type IV and V are represented in the endothelial basement 
membrane and basement membranes of smooth muscle cells of the tunica intima and tunica 
media (Shekhonin et al., 1985, Ricard-Blum, 2011, Xu, Shi, 2014).  
 
 





Figure 2 Structure of an artery wall in arterial sample in TEM analysis. 
1.3.2 Vascular smooth muscle cells 
Muscle cells are divided into three different types: skeletal, cardiac and smooth muscle cells. 
Smooth muscle cells are present in the walls of many hollow organs like in the bronchial, 
vascular, gastrointestinal, reproductive and urogenital systems, and also in the eyes. Smooth 
muscle cells are not striated as the other muscle cell types. In line with cardiac muscle cells, 
smooth muscle cells are involuntarily controlled, not branched and singly nucleated. 
Vascular smooth muscle cells (VSMCs) are one of the main components of the vascular wall. 
VSMCs regulate the blood volume, flow and blood pressure in the vessels, due to their myosin-
actin interactions, by contracting and relaxing in response to vasoactive stimuli (Michel, Li & 
Lacolley, 2012). VSMCs are located in the tunica media where they provide structural integrity 
and control the diameter of the vessel. Arteries have a greater amount of VSMCs than veins, 
thus their walls are much thicker.  
Mature VSMCs in the vessel wall can be defined as the contractile phenotype. However, 
VSMCs are sensitive to different physiological or pathological stimuli, such as growth factors, 




changes in their functional and morphological properties at different developmental stages, 
during vascular repair, and in vascular disease (Owens, 1995, House et al., 2008). VSMCs are 
very plastic cells as they can acquire a broad spectrum of different phenotypes from quiescent 
contractile to more migratory, proliferative, synthetic, endocytic, phagocytic, or osteoblastic 
ones  (Michel, Li & Lacolley, 2012). In injury or during development, VSMCs changes to 
migratory and proliferate phenotype and are then able to accumulate in the intima and 
synthesize extracellular matrix proteins. This phenotype is called synthetic cell. VSMCs also 
show considerable differences depending on their position in the arterial tree (large vs. small 
vessels), their embryologic origin and their organ-dependent microenvironment e.g. in the 
heart, brain and kidney (Michel, Li & Lacolley, 2012). 
Smooth muscle α-actin 
For different functionalities and morphological properties VSMCs have evolved a repertoire 
of appropriate contractile proteins, agonist receptors, ion channels, and signal-transducing 
molecules (Owens, 1995). The differentiated state of the VSMCs is characterized by e.g. 
specific contractile proteins and cell surface receptors (Metz, Patterson & Wilson, 2012).  One 
of the contractile proteins, widely used for characterization of VSMCs, is the smooth muscle 
α-actin. It is one of eight isoactins expressed in mammalian cells (Vandekerckhove, Weber, 
1979, Rubenstein, 1990) and the most abundant of the actin isoforms in a mature fully 
differentiated VSMC. Smooth muscle α-actin is also the most abundant protein in smooth 
muscle cells making up to 40 % of total cell protein and over 70 % of the total actin (Fatigati, 
Murphy, 1984). Other isoforms expressed by VSMCs are nonmuscle β-actin, nonmuscle γ-
actin, and smooth muscle γ-actin (Gabbiani et al., 1981).  
1.3.3 Vascular smooth muscle cells in amyloidoses 
VSMCs are involved in several vascular diseases due to their complexed signaling system and 
versatile plasticity (Michel, Li & Lacolley, 2012). They have a major role e.g. in hypertension 
(Lee et al., 1995) and atherosclerosis (Bennett, Sinha & Owens, 2016) but also in different 
amyloidoses. VSMCs are suggested to be responsible for β-amyloid deposition in the vascular 
wall in Alzheimer’s disease (Wisniewski, Frackowiak & Mazur-Kolecka, 1995) and 
synthetization of the amyloid precursor protein lactadherin in AMed amyloidosis (Haggqvist 




immunoglobulin light chains in AL amyloidosis (Vora, Kevil & Herrera, 2017). VSMCs 
participate in the formation of AL by the intracellular processing of amyloidogenic light chains, 
which is possible due to their transformation from a smooth muscle to a macrophage 
phenotype. 
1.3.4 Angiopathies in amyloidoses 
Overall, the cardiovascular system is a common target of different amyloidoses, such as AL, 
ATTR, AANF and AMed related amyloidosis (see table 1 for definitions) (Kholova, Niessen, 
2005). Wang et al. excellently summarizes the consequences of amyloid deposition depending 
on the site in the vasculature system: “If amyloid proteins deposit within the walls of the 
cerebral vasculature with subsequent aggressive vascular inflammation, it will lead to 
recurrent hemorrhagic strokes; If they deposit within the walls of the coronary artery, they 
will lead to angina pectoris, even ischemia cardiomyopathy; If they deposit within the wall of 
aorta, they will lead to hypertension, atherosclerosis, and even dissecting aneurysm 
eventually.” (Wang et al., 2017). In addition, peripheral nerve amyloid angiopathy may 
contribute to sensory and motor nerve injury (Kiuru-Enari et al., 2002, Yamashita et al., 2005). 
Cerebral amyloid angiopathies 
The best known type of amyloid angiopathy is cerebral amyloid angiopathy (CAA) which is 
defined by the deposition of amyloid within the walls of small to medium-sized blood vessels 
of the brain: leptomeningeal and cortical arteries, arterioles and, less frequently, capillaries 
and veins (Ghiso, J., Frangione, 2001). The most common manifestation of CAA is cerebral 
hemorrhage, as primary intracerebral hemorrhage (PICH), but it may also lead to ischemic 
infarction and dementia (Pezzini et al., 2009). At present CAA is known to associate with 
deposition of seven amyloid proteins, namely: Aβ, ACys, ABri, ADan, APrP, ATTR and AGel.  
CAA has been widely studied and reported in Alzheimer’s disease (AD). AD patients are 
characterized by the extracellular deposition of amyloid Aβ protein in cerebral parenchymal 
plaques and blood vessels. A large majority of the patients diagnosed with AD suffer of stroke-
like lesions or infarctions, ranging from CAA, degenerative microangiopathy compromising 
both the endothelium and smooth muscle cells, cerebral infarcts, microinfarction, white 





Hereditary cystatin C amyloid angiopathy (HCCAA,) also known as hereditary cerebral 
hemorrhage with amyloidosis of Icelandic type (HCHWA-I), is an autosomal dominant disorder 
caused by a mutation in the CST3 gene (Abrahamson et al., 1987). Variant Cystatin C is 
abundant in cerebrospinal fluid and associated with cerebral hemorrhages, typically in young 
adult carriers (Snorradottir et al., 2017). HCCAA is characterized by massive amyloid 
deposition within small arteries and arterioles of leptomeninges, cerebral cortex, basal 
ganglia, brainstem and cerebellum. Although the brain involvement is the main feature in 
HCCAA, amyloid deposits are present also in peripheral tissues such as skin, lymph nodes, 
spleen, salivary glands, and seminal vesicles. In HCCAA PICH dominates the clinical picture 
unlike in other CAA-related amyloidosis (Pezzini et al., 2009). 
Familial British dementia (FBD), is an autosomal dominant form of CAA caused by a mutation 
in the single multiexonic gene BRI2 located on the long arm of chromosome 13 (Ghiso, J. A. et 
al., 2001). FBD is characterized by progressive dementia, spastic tetraparesis and cerebellar 
ataxia in the age of 40s-50s (Verbeek, de Waal & Vinters, 2013). Amyloid angiopathy is severe 
and widespread in the brain and spinal cord with perivascular amyloid plaque formation. 
However, large intracerebral hemorrhage is a rare manifestation of the disease although the 
central nervous system is extensively loaded with amyloid (Verbeek, de Waal & Vinters, 2013). 
The amyloid subunit (ABri) was extracted from FBD brain tissues (Vidal et al., 1999).  
Familial Danish dementia (FDD) is an autosomal dominant neurodegenerative disease caused 
by a mutation in the same gene BRI2 as in FBD (Ghiso, J., Frangione, 2001). FDD is 
characterized by the existence of widespread cerebral amyloid angiopathy (CAA) in vessels of 
the retina and leptomeninges, and in vessels of the central nervous system (Vidal et al., 2009). 
Extensive amyloid angiopathy is present in the blood vessels of the cerebrum, choroid plexus, 
cerebellum, spinal cord, and retina. In spite of that, also in FDD the incidence of cerebral 
hemorrhage is rare (Vidal et al., 2009). 
In prion diseases or prionoses the etiology is related to the conversion of the normal prion 
protein PrPC into an infectious and pathogenic form PrPSC (Colby, Prusiner, 2011). The latter 
form can also accumulate as amyloid in the brain. Prionoses include Creutzfeldt-Jakob disease, 
kuru, Gerstmann-Sträussler-Scheinker disease and fatal familial insomnia in humans as well as 
scrapie, bovine spongiform encephalopathy, transmissible mink encephalopathy and chronic 
wasting disease in animals (Ghetti et al., 1996b, Prusiner, 1998, Collinge, 2001). Familial PrP-




gene (PRNP) (Jansen et al., 2010). In PrP-CAA amyloidosis is predominantly vascular in contrary 
to other prionoses. PrP amyloid fibrils are seen adjacent to and within the vessel wall 
associated with neurofibrillary lesions (Ghetti et al., 1996a). PrP-CAA has a broad spectrum of 
clinical presentations where the main signs are ataxia, spastic paraparesis, extrapyramidal 
signs and dementia.  
Transthyretin (TTR) amyloidosis is caused by deposition of wild-type (ATTRwt) or variant 
(ATTRv) amyloidogenic TTR. ATTRwt amyloidosis has traditionally been called senile systemic 
amyloidosis and ATTRv amyloidosis has been termed familial TTR amyloidosis (Pitkänen, 
Westermark & Cornwell, 1984, Koike, Katsuno, 2019). Though wild-type TTR can form 
amyloid, the hereditary form of ATTR amyloidosis is caused by autosomal dominant mutations 
in the TTR gene. The most common ATTR mutation worldwide is V30M but more than 100 
pathogenic TTR mutations are reported thus far (Kapoor et al., 2019). The phenotypes and age 
of onset varies greatly depending of the mutation. The hallmarks in ATTR amyloidosis are 
peripheral neuropathy and involvement of visceral organs (e.g. kidney and ovaries), whereas 
central nervous system involvement is atypical. ATTR amyloid deposits are present in the 
blood vessels in the brain and spinal cord, where small and medium size vessels are most 
gravely affected (Ghiso, J., Frangione, 2001). In addition to ischaemia, amyloid angiopathy has 
also been reported to cause ocular problems ATTRv amyloidosis (Kawaji et al., 2005).  
Cerebral amyloid angiopathy is found also in HGA (Kiuru, Salonen & Haltia, 1999). 
Systemic amyloid angiopathies 
Systemic amyloidoses are caused by extracellular deposition of misfolded circulating proteins 
as amyloid fibrils and affect various vital organs including the vascular system. Several 
systemic amyloidoses can involve the entire cardiovascular system. These include AL, AH, AA, 
Aβ2M, AApoAI and ATTR related amyloidosis (Kholova, Niessen, 2005). Vascular involvement 
is also reported in ALys (Benyamine et al., 2017) and in AGel (Meretoja, Teppo, 1971, Kiuru, 
Salonen & Haltia, 1999, Juusela, P. et al., 2009, Pihlamaa et al., 2016, Schmidt et al., 2019) 
related amyloidosis. Amyloid is deposited in the tunica media and tunica adventitia causing 
thickening of the wall. This often leads to obstruction and consequent ischaemia. Vascular 
involvement is less frequent in acquired amyloidoses, mostly involving small intramyocardial 




The most prevalent type of the systemic amyloidoses is light-chain (AL) amyloidosis (Merlini, 
2017). This amyloidosis is caused by misfolded monoclonal immunoglobulin light chains 
produced by plasma cells. Vascular involvement affecting medium to large arterioles and small 
arteries is actually a very typical feature in light-chain amyloidosis, it is reported in 88–90 % of 
patients (Eder et al., 2007). Abnormal vascular morphology and endothelial dysfunction is 
seen in light chain amyloidosis (Modesto et al., 2007). Also, severe pulmonary hypertension 
without an apparent cardiac or parenchymal lung involvement and portal hypertension has 
been reported (Eder et al., 2007, Norero et al., 2013). Although cardiac involvement is the 
main cause of morbidity and mortality in light chain amyloidosis (Merlini, 2017) vascular 
abnormalities do not appear to be related to it (Modesto et al., 2007). 
Similarly to AL, AH-amyloidosis is also caused by misfolded monoclonal immunoglobulin but 
in this disease amyloid is composed of immunoglobulin heavy chains. Unlike light chain 
amyloidosis, this is a rare disease with very few cases thus far reported (Picken, 2007, Manabe 
et al., 2015).  
Another common type of systemic amyloidosis is AA amyloidosis. This disease is directly 
related to inflammations. In AA amyloidosis amyloid deposits are composed mainly of the 
serum amyloid A (SAA) protein, which is a major acute phase reactant in inflammations (Real 
de Asua et al., 2014). When an abnormally high plasma concentration of SAA persists for a 
long time in serum, SAA aggregates into amyloid fibrils. The expression of cytokines, in 
particular interleukin 6, leads to overexpression of SAA by the liver (Westermark, Fandrich & 
Westermark, 2015). AA amyloidosis is typically found in patients with rheumatoid arthritis, or 
with familial Mediterranean fever, however only a small number of patients with 
inflammatory conditions will eventually develop amyloidosis (Real de Asua et al., 2014). AA 
amyloidosis affects various vital organs, like kidney, and it may also cause an increased risk of 
developing coronary artery diseases (Bulut et al., 2016). 
β2‐microglobulin (β2M) amyloidosis is known as dialysis‐related amyloidosis. Often this 
amyloidosis is a consequence of a long-term dialytic therapy but it can be found even in 
patients with a chronic renal failure before starting the dialysis (Kaneko, Yamagata, 2018). This 
suggests that the cause for Aβ2M amyloid formation is accumulation of β2M or some β2M‐
associated molecules in the body due to different reasons. β2M is the light chain of class I 
human leukocyte antigen (HLA) on all nucleated cells. The expression of β2M is normally 




Yamagata, 2018). Aβ2M is deposited predominantly in the bones, tendons and joints but also 
vascular and endocardial involvement has been described (Kholova, Niessen, 2005). β2M 
amyloidosis can also be caused by a variant β2M which is inherited in autosomal dominant 
manner. Unlike patients with dialysis-related amyloidosis, these patients have normal renal 
function and normal rates of circulating β2M (Valleix et al., 2012). However, the variant β2M 
is unstable and remarkably fibrillogenic in vitro under physiological conditions (Valleix et al., 
2012). 
Apolipoprotein AI (ApoAI) amyloidosis is a hereditary systemic disease caused by germline 
mutations in APOA1 gene. ApoAI is involved in cholesterol transport by being the main protein 
component of high-density lipoprotein particles in the plasma. Over 50 ApoAI variants are 
known, of which more than 20 have been associated with hereditary ApoAI amyloidosis 
(Moutafi et al., 2019). Probably the mutations increase the risk of proteolysis and result in 
generation of amyloid fibril-prone fragments (Westermark, Fandrich & Westermark, 2015). In 
ApoAI amyloidosis extensive visceral amyloid deposits affect the liver, spleen, and kidney, 
occasionally also the heart, nerves, larynx, and gastrointestinal tract (Rowczenio et al., 2011). 
The clinical spectrum of ApoAI amyloidosis is very heterogeneous since the organ distribution, 
age of onset, clinical features, progression rate, and prognosis are dependent on the mutation 
site (Eriksson et al., 2009). Patients with N-terminal mutations mainly suffer from hepatic and 
renal amyloidosis, while patients carrying C-terminal mutations usually develop cardiac, 
laryngeal, and cutaneous amyloidosis (Eriksson et al., 2009). Overall, typical symptoms in 
ApoAI amyloidosis include hypertension, proteinuria and renal impairment (Rowczenio et al., 
2011). 
Lysozyme amyloidosis is a rare autosomal dominant hereditary amyloidosis caused by 
lysozyme derived amyloid deposits (ALys). Lysozyme is a ubiquitous bacteriolytic enzyme 
synthesized by hepatocytes, polymorphonuclear leucocytes and macrophages and so far eight 
different variants of lysozyme leading to amyloidosis have been reported (Li, Z. et al., 2019). 
Lysozyme amyloidosis mainly involves the digestive tract, liver, spleen, kidneys, lymph nodes, 
skin, and lachrymal and salivary glands. Also vascular involvement has been reported in many 
organs (Benyamine et al., 2017).  





Localised amyloid angiopathies 
Three different localised amyloidoses affect the vascular system. These are AANF, AMed and 
Aβ related amyloidoses. All of them are age-related amyloidoses.  
AANF related amyloidosis is also known as isolated atrial amyloidosis (IAA). The fibril protein 
deposited in IAA is the atrial natriuretic factor (ANF), a peptide hormone synthesized and 
secreted predominantly by atrial cardiomyocytes (Johansson, Wernstedt & Westermark, 
1987). IAA is strictly localized to the atrium of the heart, mostly to the auricles, and very small 
vessels are commonly involved (Cornwell, Westermark, 1980). The incidence of IAA increases 
with age, reaching 90% in the ninth decade (Kawamura et al., 1995). Hypertension, diabetes 
mellitus, hypertrophy of the heart, coronary atherosclerosis, and dilatation of the atria show 
no significant relationship to the incidence or severity of IAA (Steiner, Hajkova, 2006). 
AMed or medin amyloidosis (formerly senile aortic amyloidosis) is the most prevalent of 
amyloidoses. Amyloid is found in the tunica media of aortic walls of almost 100 % of the 
population above 50 years of age (Mucchiano, Cornwell & Westermark, 1992). The precursor 
protein for medin is lactadherin which is synthesized in VSMCs. Medin peptides are deposited 
locally to the aorta (Haggqvist et al., 1999) and may increase the risk for aortic rupture by 
killing the smooth muscle cells and inducing degradation of elastin and collagen (Peng et al., 
2007). 
Alzheimer’s disease is also a localised amyloidosis. 
1.4 Elastic fibres 
Elastic fibres are essential insoluble components of the extracellular matrix (ECM) in dynamic 
tissues like skin, lungs, and blood vessels as they enable critical properties of elasticity and 
resilience. Elastic fibres are assembled in a highly organized process during development in 
mid-gestation and they are able to maintain their function for a lifetime (Kielty, Sherratt & 
Shuttleworth, 2002). Since elastic fibres play a vital role for example in the cardio-respiratory 
system, it has been suggested that age-related failures of elastic fibres could even be the 
limiting factor for a human life expectancy to 100-120 years (Robert, Robert & Fulop, 2008).  
Elastic fibres are formed of an amorphous, crosslinked elastin core and a fibrillin-rich 




principal structural components of microfibrils. There are three different isoforms of fibrillin, 
fibrillin-1, -2 and -3, of which fibrillin-2 is expressed during early development and fibrillin-1 is 
predominant in mature microfibrils (Sherratt, 2009). Microfibrils form loosely packed parallel 
bundles in tissues (Kielty, Sherratt & Shuttleworth, 2002). Elastin is secreted as a soluble 
precursor protein, tropoelastin, and after a transfer to the microfibril scaffold it is 
enzymatically converted to a mature form by lysyl oxidase (LOX) or LOX-like proteins (Sherratt, 
2009). Elastin is the most prevalent protein in elastic fibres comprising around 90 % of the 
structure (Baldwin et al., 2013). Elastin is a quite exceptional protein since it is extremely 




Figure 3 Tortuous shaped lamina elastica interna (arrows) in artery of normal healthy 
individual seen in TEM analysis. Small dark dots are electron-dence microfibrils and 
lighter amorphous material is elastin. 
 
Interestingly, elastin has a special role in AMed related amyloidosis since it is proposed to 
initiate amyloidogenesis by binding to lactadherin, which is the precursor protein of medin 
amyloid (Larsson et al., 2006). In addition, elastin-like peptides interacting with heparan 





The degradation of mature elastin normally progresses very slowly, over years or decades. The 
rate and nature of age-related elastic fibre degradation varies between individuals and 
anatomical sites (Sherratt, 2009). This degradation process is called elastolysis and it is 
assumed to be caused by a disturbance in the normal balance between proteinases and their 
inhibitors (Werb et al., 1982). This can be observed, for example, in vessel walls during ageing 
and atherosclerosis (Kunecki, Nawrocka, 2001). Elastin can be degraded by aggressive 
proteolytic enzymes known as elastases (Baud et al., 2013). Human elastases have been 
identified within three different classes of proteinases: cysteine, serine, and 
metalloproteinases (Hornebeck, Emonard, 2011). Cysteine proteinases, mostly different types 
of cathepsins, are localized in lysosomes involved in intra-cellular degradation (Budd et al., 
2013). Serine proteinases are a wide group of proteinases degrading components of the ECM. 
Serine elastases, which belong to this proteinases family, can be further divided into three 
different groups: pancreatic and neutrophil elastases, and cathepsin G. The first is secreted in 
the pancreas and has a major role in digestion, while the latter two are secreted in azurophil 
granules of neutrophils in inflammation, hence they are able to eliminate pathogens and break 
down tissues at inflammatory sites (Korkmaz et al., 2010). 
The key players of ECM degradation in normal physiological processes are metalloproteinases, 
mainly matrix metalloproteinases (MMPs) (Budd et al., 2013). Matrix metalloproteinases 
contain Zn2+ ions/atoms and cleave the peptide bonds on the amino-terminal side. MMPs can 
be grouped into different subtypes according to their substrate specificity or cellular 
localization e.g. collagenases, gelatinases, stromelysins, matrilysins, metalloelastases and 
membrane type-MMPs. Four MMPs are known to be capable to degrade insoluble elastic 
fibres: MMP-2 (72 kDa gelatinase), MMP-7 (matrilysin), MMP-9 (92 kDa gelatinase) and MMP-
12 (macrophage metalloelastase) (Mecham et al., 1997). The cascades between proteinases 
are complex since many proteinases regulate the activity of others by cleaving the protein 
precursors (pro-proteins) into mature active forms. Many MMPs have this characteristic, for 
example, pro-MMP2 is a substrate for MMP-14 (Budd et al., 2013).  
Elastases can efficiently bind elastin but also onto cell surface-associated proteins such as 
heparan sulfate proteoglycans (Hornebeck, Emonard, 2011). Immobilization of elastin at the 




elastolysis are, among other properties, potent inducers of protease expression amplifying 
elastin degradation (Hornebeck, Emonard, 2011) and can interestingly even form amyloid-like 
fibers (Bochicchio, Pepe & Tamburro, 2007). Also, reactive oxygen species, calcification, 
aspartic acid racemization, lipid accumulation and mechanical fatigue may cause alteration of 
the elastic fibre structure favouring elastolysis (Robert, Robert & Fulop, 2008, Sherratt, 2009).  
Elastases are inhibited by several different enzymes, for example, serine proteases are 
inhibited by serpins such as plasminogen activator inhibitors (PAI) and MMPs are inhibited by 
tissue inhibitors of metalloproteinases (TIMPs) (Budd et al., 2013). Additionally, many other 
factors also regulate the activity of proteinases. As an example, transforming growth factor-β 
(TGFβ) reduces collagenase production and stimulates the expression of TIMPs, leading to an 
overall inhibition of ECM degradation and resulting in excessive ECM accumulation (Akhurst, 
Hata, 2012). On the other hand, MMP-2 and MMP-9 cleave latent TGFβ in to an active form 
(Akhurst, Hata, 2012).  
1.4.2 Amyloid deposition on elastic fibres 
Amyloid fibrils tend to accumulate along elastic fibers (Winkelmann, Peters & Venencie, 1985, 
Sepp et al., 1990, Mucchiano, Cornwell & Westermark, 1992). The microenvironment on the 
surface of elastic fibre must be somehow favourable for the amyloid deposition. It has been 
suggested that serum amyloid P component (SAP) has an important role in this. SAP is 
associated normally with microfibrils of elastic fibers in healthy individuals (Breathnach et al., 
1983, Breathnach, Pepys & Hintner, 1989). Unfortunately it also binds effectively to different 
types of amyloid fibrils that could encourage amyloid accumulation on the elastic fibre (Pepys 
et al., 1979, Pepys et al., 1982). AGel deposits have been reported to include SAP as well (Kiuru, 
Salonen & Haltia, 1999). SAP may also form a nidus for amyloid deposition (Winkelmann, 
Peters & Venencie, 1985). On the other hand, SAP is shown to act as an elastase inhibitor 
protecting not only normal elastic fibers but also pathological amyloid fibrils from proteolytic 
cleavages (Li, J. J., McAdam, 1984, Sepp et al., 1990). 
1.4.3 Elastolysis in amyloidoses 
Although amyloid fibril accumulation along elastic fibres is a widely recognized phenomenon, 




conditions, like in atherosclerosis and UV-induced photoaging elastolysis, fragmentation of 
elastic fibres has been under intensive research, whereas only six cases are reported of 
amyloid elastosis to date. All of these cases are considered cutaneous amyloidosis, both 
systemic and localized amyloidosis types (Winkelmann, Peters & Venencie, 1985, Sepp et al., 
1990, Vecchietti et al., 2003, Bocquier et al., 2008, Santos-Briz et al., 2010, Marchand et al., 
2013). Also, in HGA elastolysis has been described in the skin (Kiuru-Enari, Keski-Oja & Haltia, 
2005). Apart from these, only a few cases of elastolysis (or elastosis) of other amyloid types 





2 Hereditary gelsolin amyloidosis 
Hereditary gelsolin amyloidosis (HGA) is a rare systemic amyloidosis inherited in an autosomal 
dominant pattern (Meretoja, 1969, Kiuru-Enari, Haltia, 2013). HGA is also known as gelsolin-
related amyloidosis (AGel amyloidosis), familial amyloidosis Finnish type (FAF), familial 
amyloid neuropathy type IV and Meretoja disease (OMIM #105120). It was originally reported 
in Finland by an ophthalmologist Jouko Meretoja in 1969 who recognized this new disease 
and later diagnosed more than 250 patients in Finland (Meretoja, 1969, Meretoja, 1976). HGA 
is a member of the Finnish disease heritage which includes 36 different inherited diseases that 
are more frequent in Finland than in any other population. Although HGA is nowadays 
reported worldwide, Finland still has the largest known patient population with an estimated 
prevalence of 1:6 000 (Norio, 2003) or even 1:1 040 in Kymenlaakso area (Meretoja, 1973). 
With the prevalence this high HGA is considered one of the most common diseases of the 
Finnish disease heritage. According to the latest haplotype analysis of Finnish HGA families, all 
Finnish HGA patients have the same ancestor (Mustonen et al., 2018), as Meretoja proposed 
already some decades ago (Meretoja, 1976). HGA can appear in heterozygous or homozygous 
forms. 
Despite the patients of Finnish origin, the distribution of HGA reaches all over the world. At 
present, HGA has been identified already in many European countries, the United States, 
Japan, Brazil, Iran (Kiuru, 1998, Kiuru-Enari, Haltia, 2013), India (Maramattom, Chickabasaviah, 
2013), Mexico (Gonzalez-Rodriguez et al., 2014), Canada (Alabdali et al., 2015), Korea (Park et 
al., 2016), and Argentina (Lucero Saa et al., 2017). Although HGA could still be underdiagnosed 
(Ardalan, Shoja & Kiuru-Enari, 2007) or even misdiagnosed (Juusela, P. et al., 2009), the 
growing awareness of HGA enables new cases to be found continuously from different parts 
of the world.  
2.1 Gelsolin 
Gelsolin was found in 1979 by Yin and Stossel who isolated an unknown protein from rabbit 
lung macrophages (Yin, Stossel, 1979). They noticed that this protein binds to actin and 
modulates the network structure of actin filaments by shortening them. In the cells 




is continuously treadmilling in this gel-sol transformation. Because the unknown protein was 
found to be a regulator of this process it was named gelsolin. Actually gelsolin was also found 
by two other research groups at about the same time but they called this protein as actin-
destabilizing factor (Chaponnier et al., 1979) and brevin (Harris, D. A., Schwartz, 1981, Wilkins, 
Schwartz & Harris, 1983), respectively. 
Different isoforms 
Gelsolin has different isoforms, a cytosolic and a secreted isoform. The cytosolic isoform was 
the first one to be described (Yin, Albrecht & Fattoum, 1981) but soon also the secreted 
isoform was found from plasma (Yin et al., 1984). These two isoforms are generated by an 
alternative transcriptional initiation site and mRNA splicing from the single gelsolin GSN gene 
on chromosome 9 (9q33.2) (Kwiatkowski et al., 1986, Kwiatkowski, Westbrook et al., 1988). 
The cytosolic gelsolin contains 731 amino acids and its molecular mass is 81 kDa whereas 
secreted gelsolin contains 782 amino acids and its molecular mass is 86 kDa (UniProt - P06396 
GELS_HUMAN). The secreted gelsolin has a 24 amino acid long extension and a 27 amino acids 
long signal sequence in the N-terminus. It also has a disulfide bond between cysteine residues 
at positions 188 and 201 (Wen et al., 1996), and is more positively charged than the cytosolic 
isoform (Yin et al., 1984). The 24 amino acids N-terminal extension might have some 
functionality since it takes a defined, fixed position on the surface of the secreted gelsolin 
(Fock et al., 2005).  
Furthermore, a third isoform, gelsolin-3, has been described. Gelsolin-3 is a cytosolic protein 
which has 11 additional residues at the N-terminus. Gelsolin-3 is expressed mainly in the brain, 
lungs and testis, but its specific function is still unknown (Vouyiouklis D.A., Brophy P.J., 1997). 
Actin binding and modulation 
Actin is a highly conserved protein (molecular mass 42 kDa) forming microfilaments in the 
cytoplasm. Actin is the most abundant protein in most eukaryotic cells and it has six isoforms 
encoded by six different genes: α-skeletal, α-cardiac, α-smooth, γ-smooth, β-cytoplasmic and 
γ-cytoplasmic isoforms (Perrin, Ervasti, 2010). Actin occurs in cells both as a monomeric 
globular protein (G-actin) and polymerized into actin filaments (F-actin). The actin 




and viscoelastic properties of the cells and critical for the cell motility (Dominguez, Holmes, 
2011).  
Actin participates in more protein-protein interactions than any known protein. About 300 
actin-binding proteins (ABPs) are reported in total and more than 100 of those have 
established roles in modulation of actin filaments (Nag et al., 2013). Gelsolin is a founding 
member of one superfamily of actin-binding proteins. Gelsolin superfamily includes at least 
six other proteins in addition to gelsolin: villin, adseverin (also known as scinderin), capG, 
advillin, supervillin and flightless I (Kwiatkowski, 1999, Silacci et al., 2004, Nag et al., 2013). Of 
those, adseverin has the highest degree of homology (60 %) with gelsolin (Lueck, Brown & 
Kwiatkowski, 1998).  
Gelsolin contains six gelsolin-like domains named G1 to G6 from the N- to the C-terminus. 
Each one of the domains comprise 97-118 residues folded into a 5- or 6-stranded β-sheet 
between a long helix that is approximately parallel, and a short helix that is approximately 
perpendicular, to the strands in the sheet (Burtnick et al., 1997, Burtnick, Robinson & Choe, 
2001). Gelsolin is divided into two homologous halves, both containing threefold repeats: G1–
G3 and G4–G6 (Kwiatkowski et al., 1986). Domains G1 and G4 contain the G-actin-binding sites 
whereas G2 binds to F-actin. In calsium ion (Ca2+) free environment G1-G6 domains pack 
together to a compact globular structure where actin binding sequences are inside of this 
structure and cannot interact with actin (Burtnick, Robinson & Choe, 2001).  
Gelsolin severs actin filaments stoichiometrically and forms a cap structure to the barbed (+) 
-end of the newly generated actin filament which prevents reannealing of actin fragments 
(Harris, H. E., Weeds, 1984, Sun et al., 1994). Severing proceeds at the pointed (-) -ends, 
resulting in the rapid disassembly until an equilibrium is established between capped 
filaments and free gelsolin (Figure 4). Actin filament severing requires domains G1 and G2 





Figure 4 Actin filament severing by gelsolin. Gelsolin severs actin filaments at the 
pointed (-) -ends and forms cap structures to the barbed (+) -end of the newly 
generated actin filament which prevents reannealing of actin fragments. 
 
Regulation 
Gelsolin activity is regulated by Ca2+ (Yin, Zaner & Stossel, 1980, Yin, Albrecht & Fattoum, 1981, 
Yin et al., 1981, Janmey et al., 1985), intracellular pH (Selve, Wegner, 1987), phosphoinositides 
(Janmey, Stossel, 1987, Lin et al., 1997) and tyrosine kinase phosphorylation of gelsolin (De 
Corte, Gettemans & Vandekerckhove, 1997).  
The isolated N-terminal half can bind and cap two actin monomers and can sever F-actin 
without free Ca2+ whereas the C-terminal half binds a single actin only when free Ca2+ is 
present. Ca2+ dependent regulation is based on C-terminal tail helix latch mechanism where 
the tail helix is responsible for transmitting Ca2+ binding from the C-terminal half to the N-
terminal half of gelsolin (Lueck et al., 2000). When Ca2+ in micromolar concentration unlatches 
the tail helix, the F-actin binding site on G2 will become exposed and the G3–G4 linker adopts 
an extended conformation that enables the two halves of gelsolin to separate from each 
other. Subsequent opening of the G1–G3 and G4–G6 allows remarkable rearrangement of the 
relative positions of the domains which is required for active conformation of gelsolin (Lin, 
Mejillano & Yin, 2000, Choe et al., 2002) (Figure 5). The tail helix latch is responsible also for 




Intracellular pH is another essential factor regulating actin cytoskeleton reorganization via 
gelsolin. It has been shown that severing activity decreases with pH deviating from neutral. 
This is result from a structural and/or charge changes of gelsolin and actin molecules (Selve, 
Wegner, 1987, Lamb et al., 1993). At lower pH gelsolin does not need Ca2+ and at higher pH 
gelsolin and actin are departed because of the repulsion force. 
Phosphatidylinositol 4,5-bisphosphate (PIP2) is a regulator of gelsolin that favors filament 
uncapping and actin polymerization (Janmey, Stossel, 1987). PIP2 inhibits interactions 
between free gelsolin and actin. It also uncaps actin filaments by disrupting pre-existing 
interactions with gelsolin (Janmey, Stossel, 1987). Binding sites for PIP2 on gelsolin are within 
the G1-G2 linker (residues 135–142), in an area that overlaps the G2 F-actin-binding site 
(residues 161–169), and in the G5-G6 linker (residues 620–634) (Feng et al., 2001). The binding 
is modulated by calcium and pH (Lin et al., 1997). 
 
Figure 5 Actin filament severing by gelsolin. In the first phase gelsolin is activated by 
calcium ions (Ca2+) that opens the structure of gelsolin. In the second phase the N-
terminal side of gelsolin binds to actin when G1 domain’s active site is able to interact 
with actin leading to severing of actin filament. In the third and last phase C-terminal 
side of gelsolin binds to barbed end (+-end) of actin filament and forms cap structure. 






Distribution and function 
Gelsolin is mainly produced by the smooth and striated muscle cells, although it is expressed 
in various cell and tissue types including nervous tissue (Kwiatkowski, Mehl & Yin, 1988, 
Kwiatkowski, Mehl et al., 1988, Tanaka, J., Sobue, 1994, Paunio, T. et al., 1997). In the 
cytoplasm gelsolin is located in the sites that are rich in actin filaments (Cooper et al., 1988). 
Properties of the cytoskeleton depend on parameters, such as actin filament length, flexibility, 
concentration and presence of cross-links. Cytosolic gelsolin participates the regulation of 
cellular morphology, function, and motility of cells by severing, capping and nucleating 
activities on actin filaments (Silacci et al., 2004). 
The roles of secreted gelsolin are also associated to actin severing. Gelsolin is a crucial factor 
in apoptosis in different ways. In cellular death and lysis, actin is released into extracellular 
space ending up in blood plasma. Ionic strength, pH and temperature in the plasma favor the 
elongation of F-actin filaments which could interfere blood flow through in microcirculatory 
vessels (Burtnick, Robinson & Choe, 2001). Together with other plasma actin-binding protein, 
vitamin D-binding protein (DBP), gelsolin appears to "neutralize" actin in its monomer and 
polymeric forms (Haddad et al., 1990). In apoptosis gelsolin is cleaved from a long linker site 
connecting homologous halves (G1-G3 and G4-G6) by caspase-3 and after that it is able to 
cleave actin without Ca2+ regulation (Sun et al., 1999). Excess of N-terminal gelsolin induces 
apoptosis, whereas gelsolin null neutrophils have delayed onset of apoptosis (Kothakota et 
al., 1997). On the other hand, gelsolin has suggested to act also as an inhibitor of the apoptotic 
process (Silacci et al., 2004). For example, Jurkat cells exhibited a phenotype more resistant 
to apoptosis when gelsolin was expressed threefold more than in wild-type cells (Ohtsu et al., 
1997). The expression of gelsolin is specifically down-regulated in 60-90 % of tumours during 
carcinogenesis of breast, colon, stomach, bladder, prostate, and lung (Tanaka, M. et al., 1995, 
Asch et al., 1996, Kuzumaki et al., 1997, Spinardi, Witke, 2007). These observations suggest 
that gelsolin down-regulation in tumours may be one mechanism for tumours to evade 
apoptosis. Interestingly, the possible protective effect of gelsolin in cancer could be evident in 
HGA patients as they have higher concentration of gelsolin in plasma (Paunio, Tiina et al., 
1994) and less fatal cancers compared to general Finnish population (Schmidt et al., 2016).  
Gelsolin has an important role in the cellular response of inflammation. In addition to actin 
severing, gelsolin is known to participate in Fc-receptor and integrin-mediated phagocytosis, 




hemostatic, inflammatory, and fibroblast responses are blunted (Witke et al., 1995). Other 
studies have shown that the plasma gelsolin level decreases dramatically as a result of major 
trauma, and that reinfusion of recombinant gelsolin can protect against lung damage 
associated with major burn injury and other types of insults (Silacci et al., 2004). Low gelsolin 
level (less than 25 % of normal level) might predict secondary inflammation and tissue injury 
and that can be an indicator of critical care complications (Bucki et al., 2008). For this same 
reason gelsolin has been suggested to be used as a prognostic marker in sepsis (Horvath-Szalai 
et al., 2017). Gelsolin is also involved in chronic inflammatory diseases such as rheumatoid 
arthritis. It has been confirmed that gelsolin expression is lost in rheumatoid synovial 
fibroblasts leading to severe alterations in cytoskeletal organization (Aidinis et al., 2005). 
Interestingly, gelsolin might have a role in Alzheimer’s disease as well. Gelsolin has been 
shown to behave as an anti-amyloidogenic, anti-oxidant and anti-apoptotic factor in a 
transgenic mouse model of Alzheimer's disease where gelsolin forms a complex with Aβ 
protein and reduces the amyloid load (Chauhan, Ji & Chauhan, 2008). It has also been shown 
that gelsolin is proteolytically cleaved by caspase-3 in the brains of individuals with 
Alzheimer's disease probably due to the oxidative stress (Ji et al., 2009). 
Gelsolin is related to different types of cardiac injuries, including pressure overload, dilated 
and ischemic cardiomyopathy, myocardial infarction, and end-stage heart failure where the 
expression of gelsolin is increased (Li, G. H. et al., 2012). Gelsolin is present also in human 
platelets (Lind, Yin & Stossel, 1982). Platelet activation by either G- or F-actin may be regulated 
by the local concentrations of gelsolin and DBP. These two proteins inhibit platelet 
aggregation in a manner that can be explained by their effects on actin’s filament structure 
(Vasconcellos, Lind, 1993).  
Other functions of gelsolin are related for example to multiple sclerosis where gelsolin 
decreases actin toxicity and inflammation in a mouse model (Li-ChunHsieh et al., 2015). In 
airway smooth muscle relaxation and activation of gelsolin may contribute to relaxation 
(Mikami et al., 2017). Gelsolin has also been isolated in complexes of integrins, lipases and 
kinases. Gelsolin may alter lipid signaling pathways, either through direct binding to these 
proteins or through joint binding to clustered phosphoinositides (Kwiatkowski, 1999). 
Furthermore, gelsolin regulates Rac expression and is a downstream effector of the Ras-PI3K 
signaling pathway in gelsolin-induced cellular invasion. In phagocytosis of collagen, gelsolin 




2.1.1 Causative mutation of gelsolin 
Originally systemic HGA was found to be caused by two different mutations of the same codon 
in the GSN gene, c.640G>A or c.640G>T (formerly G654A or G654T) (Levy et al., 1990, Maury 
et al., 1990). On the protein level these mutations cause substitutions p.D187N or p.D187Y 
(also known as p.D214N or p.D214Y when the nomenclature includes the 27-residue signal 
peptide) (Ghiso, J. et al., 1990, Haltia et al., 1990, Maury, 1991, de la Chapelle et al., 1992). 
The mutated, or variant, gelsolin protein is misfolded, therefore it undergoes abnormal 
enzymatic cleavages by furin and matrix metalloproteinase 14 (MMP-14). First cleavage takes 
place in the Golgi complex by furin (Chen et al., 2001, Huff et al., 2003) and it generates a C-
terminal fragment termed C68 (Maury, Rossi, 1993, Paunio, T. et al., 1994). The second 
cleavage occurs on the cellular plasma membrane by MMP-14 (Page et al., 2005). As an end 
result of these pathological cleavages the gelsolin protein turns to amyloidogenic fragments, 
sized 5 and 8 kDa (Figure 6). Further these fragments form AGel fibrils at extracellular sites of 
many tissues (Solomon et al., 2009). Fibril formation is accelerated by heparin (Suk et al., 2006, 
Solomon et al., 2011), 1-palmitoyl-2-(9’-oxononanoyl)-sn-glycero-3-phosphocholine 
(Mahalka, Maury & Kinnunen, 2011), and apolipoprotein E (Soto et al., 1995). The 
amyloidogenicity of gelsolin is also controlled by pH (Ratnaswamy et al., 1999) and Ca2+ 
binding (Page et al., 2004).  
The mutation locates in the G2 domain in gelsolin and affects both regulatory (Ca2+) and actin-
binding sites in gelsolin (Sun et al., 1999, Burtnick et al., 2004, Nag et al., 2009). It is presented 
that pathological cleavage cascade of variant gelsolin is actually initiated by the inability of the 
mutant domain 2 to bind Ca2+ (Page et al., 2004). It is also shown that any disruption in G2 and 
G3 domain interaction leads to increased furin cleavage (Zorgati et al., 2019). However, only 
the secretory form of gelsolin is assumed to be the source of amyloid in HGA (Kangas et al., 
1996). In plasma the actin severing and nucleating activity of variant gelsolin is less than 5 % 
of normal values in homozygous HGA patients and in heterozygous HGA patients the severing 
activity is reduced by about 50 % in plasma (Weeds et al., 1993). 
Other mutations in the GSN gene causing AGel fibril accumulation have been found quite 
recently; c.580G>A (p.G167R) (Sethi et al., 2013, Boni et al., 2018), c.633C>A (p.N184K) 
(Efebera et al., 2014, Boni et al., 2016) causing renal amyloidosis, and c.1375C>G causing 




         
Figure 6 Proteolytic cleavage of the variant gelsolin. The structure of the variant 
gelsolin opens for the furin cleavage and then the C68 fragment is cleaved further to 




AGel accumulates primarily at the basal lamina of various types of epithelial cells, smooth, 
skeletal and cardiac muscle cells, and in the epi- and perineurium of peripheral nerves and in 
meninges  (Meretoja, Teppo, 1971, Haltia et al., 1990, Kiuru et al., 1994, Kiuru et al., 1995, 
Kiuru-Enari et al., 2002). Deposition of AGel in arterial walls is encountered in nearly every 
organ including skin, muscle, rectum, nerve, kidney and salivary glands (Meretoja, Teppo, 
1971, Kiuru, 1992, Kiuru et al., 1994, Kiuru-Enari et al., 2002, Juusela, P. et al., 2013, Pihlamaa 
et al., 2016). In the eyes AGel deposits are found especially in the corneal lattice lines, under 
Bowman’s membrane, and in the scleral drainage area. It is suggested that AGel amyloid is 
produced locally in the eyes, especially in the cornea, conjunctiva, sclera, and ciliary muscle 
(Kivelä et al., 1994). The increasing amount of amyloid is associated with the severity of clinical 
features in HGA (Pihlamaa et al., 2016). 
The pathomechanisms on cellular and molecular level causing HGA amyloidosis are not fully 
clarified. AGel depositions with subsequent cytotoxic effects are thought to contribute to the 
pathogenesis (Anan et al., 2010). Similarly, to other amyloidoses, the formation of oligomeric 
aggregates itself during the amyloidogenesis with proteotoxic and cytotoxic effects has been 




formation accelerators, specific pathological chaperons, have been recognised in AGel 
deposits as well, such as apo E, SAP and alpha-1-chymotrypsin (Kiuru, Salonen & Haltia, 1999).  
2.3 Clinical features 
In heterozygous patients HGA is a slowly progressing usually late-onset disease (Kiuru-Enari, 
Haltia, 2013) with no significant affect to the patients’ life expectancy (Schmidt et al., 2016). 
However, it causes many difficulties to the patients already at a younger age (Laine et al., 
2010). The main, and usually the first, symptom is corneal lattice dystrophy (CLD), that occurs 
at thirties or forties (Meretoja, 1969, Meretoja, 1973, Nikoskinen et al., 2015). This 
ophthalmological manifestation often causes recurrent corneal erosions and visual 
impairment or even loss of vision at an advanced age. Patients frequently suffer from dry and 
irritable eyes and photophobia (Meretoja, 1969, Kiuru, 1992).  
Other characteristics of HGA are neurological and dermatological manifestations. Neuropathy 
involves most typically cranial and peripheral nerves, while autonomic and central nervous 
signs are mainly minor (Kiuru et al., 1994, Kiuru, Seppalainen, 1994, Kiuru et al., 1995). Patients 
usually develop distal paresthesias and manual clumsiness and slowly progressing, commonly 
bilateral facial nerve paresis (Pihlamaa et al., 2011). Dysphagia and dysarthria, balance 
problems, even prominent ataxia with severely impaired mobility can occur too, particularly 
in aged patients (Tanskanen et al., 2009). Loose and hanging skin, known as cutis laxa, is a 
prominent feature of HGA contributing for example to progressive premature facial aging and 
an increased fragility of the skin (Kiuru et al., 2000, Kiuru-Enari, Keski-Oja & Haltia, 2005, 
Pihlamaa et al., 2011) (Figure 7). Atrophy of the skin is associated with symptoms like itching 
and dryness, increased vulnerability, and abnormal scarring. In addition, the hair of the body 
and scalp can be diminished or lost. Together this characteristic clinical triad of neurological, 
dermatological, and ophthalmological manifestations can cause among other things severe 
facial disfigurement, hypomimia, and loss of vision, which severely decrease quality of life 






Figure 7 Clinical characteristics of HGA in 79-year-old male patient. HGA patients have 
severe looseness of the skin (cutis laxa) contributing to many difficulties such as 
hypomimia, dysarthria and drooling together with facial and bulbar paralysis. A) 
Characteristic facial features with drooping appearance. Regardless of several 
corrective plastic surgeries the patient shows serious hanging of the eyelids and mouth. 
B) Tongue is furrowed and macroglossic. C-E) Cutis laxa affected abnormally lax, folded, 
and unelastic skin of the scalp, the thumb and the back. D and F) Lost elasticity is noted 
in a pressure test where the skin maintains the deformed state 2-5 min after pressure. 
Figures published with the permission of the British Journal of Dermatology (Kiuru-
Enari, Keski-Oja & Haltia, 2005). 
 
Apart from progressive facial nerve and cutaneous tissue impairment this amyloidosis also 
causes various oral symptoms. HGA patients have often reduced saliva secretion with 
problems of dry mouth, also periodontitis and, loose and cracked teeth (Juusela, P. et al., 
2013, Juusela, P. L. et al., 2015). Furrowing and fasciculations of the tongue is typical in older 
patients, reminiscent of bulbar amyotrophic lateral sclerosis which may result even in 
misdiagnosis, while macroglossia is rare (Kiuru, Salonen & Haltia, 1999, Kiuru-Enari, Haltia, 




drooling. Sleep apnea due to pharyngeal tissue laxity can also occur in HGA (Kiuru, Nieminen 
& Partinen, 1999). 
Although the penetrance of HGA is 100 %, the clinical phenotype can vary greatly between 
different patients (Kiuru, 1998). There might be gender related issues as well since in women 
the symptoms and signs develop at younger age and are more common than in men (Atula et 
al., 2016). The homozygous form of HGA is very rare and has been reported only in few cases 
(Meretoja, 1973, Maury et al., 1992, Ardalan, Shoja & Kiuru-Enari, 2007). The homozygous 
patients have an early onset and potentially fatal outcome even before the age of 30 due to 
accumulation of amyloid in the kidneys. Renal involvement in HGA is characterized by mainly 
amyloid glomerulopathy, in severe cases with subsequent nephrotic syndrome (Maury, 1993). 
In heterozygotes amyloid glomerulopathy is usually subclinical, or associated with only minor 
proteinuria (Kiuru 1992).  However,  they may also manifest with severe renal involvement 
(Kiuru-Enari, Haltia, 2013, Yamanaka et al., 2013, Sethi et al., 2017), which based on recent 
studies seems to be more common than earlier considered (Nikoskinen et al., 2015). 
2.3.1 AGel amyloid angiopathy 
In the vascular system AGel accumulation is mainly concentrated to small- and medium-sized 
arteries, arterioles and capillaries, while veins are only rarely affected (Meretoja, Teppo, 
1971). In arteries, the tunica media particularly is encroached on by AGel deposits. HGA 
patients with cutis laxa have an increased fragility of the skin and risk for intracutaneous 
bleeding (Kiuru et al., 2000, Kiuru-Enari, Keski-Oja & Haltia, 2005). HGA patients express more 
hemostatic derangements, for example they often report superficial bruises after minor 
trauma, and may sometimes require blood transfusions after surgical operations (Kiuru et al., 
2000, Laine et al., 2010). Although patients wounds seem to heal normally, they have a 
tendency for noticeable postoperative swelling and hematomas, which could relate to the 
amyloid angiopathy (Pihlamaa et al., 2011). HGA patients also suffer more often from cardiac 
diseases and arrhythmias, and the consumption of cardiovascular medication is significantly 
increased (Laine et al., 2010, Nikoskinen et al., 2015). Interestingly, a recent study shows that 
AGel deposits are present in the myocardium and cardiac blood vessels in all studied HGA 
patients (n=25) (Schmidt et al., 2019). Concerning nerve tissues, the AGel amyloid angiopathy 
is particularly prominent in proximal portions of the spinal nerves (Kiuru, Salonen & Haltia, 




amyloid neuropathies in general (Kiuru-Enari et al., 2002). Cerebral hemorrhages have also 
been reported. Signs of abnormal vascular permeability in cerebral tissues were observed in 
an HGA brain autopsy study (Kiuru, Salonen & Haltia, 1999). Minor neuropsychiatric changes 
in HGA could be involved with microhemorrhages or microcalcifications found in magnetic 
resonance imaging of brains in HGA patients (Kantanen et al., 2014). 
2.4 Current treatment and future prospects 
Treatment at present is based only on alleviation of symptoms. Eyes are treated with 
lubricants and topical antibiotics when needed. Regular ophthalmological follow-up is 
important, apart from corneal and sicca problems patients can develop glaucoma and 
cataracts. Only in severe cases corneal transplantations are considered as the failure rate is 
about 50 % due to surface complications (Mattila et al., 2015). Facial symptoms are treated 
with plastic surgery but due to relentless disease progression patients need selected 
techniques and repeated surgery (Pihlamaa et al., 2011). A novel grading method for bilateral 
facial paralysis is established for evaluation of disease progression and necessity for the 
surgical treatment (Pihlamaa et al., 2015). Other skin problems, like itching and dryness, are 
relieved with ointments. Also, dryness in the mouth can be alleviate with suitable products 
but careful dental care is essential (Juusela, P. L. et al., 2015). Homozygous and rare 
heterozygous patients with severe nephrotic syndrome need dialysis or even kidney 
transplantation (Maury et al., 1992, Ardalan, Shoja & Kiuru-Enari, 2007, Nikoskinen et al., 
2015). The outcome of renal transplant can be positive, without recurrence of proteinuria at 
least during a 6-year follow up (Shoja et al., 2009).  For conduction abnormalities cardiological 
follow-up, sometimes pacemaker treatment, may be needed (Schmidt et al., 2019). 
So far, specific treatment of HGA is unfortunately not available for patients. Hypothetically, 
on cellular level AGel formation could be prevented or diminished by inhibiting the enzymes 
in the cleavage cascade of variant gelsolin. It has indeed also been shown that for example 
with proprotein convertase inhibitors, like α1-antitrypsin Portland (α1-PDX), the furin 
cleavage of variant gelsolin can be inhibited (Kangas, Seidah & Paunio, 2002). However, the 
inhibition of furin and MMP-14 proteases would with very high probability encounter 





A novel strategy for HGA therapy, which is inhibiting furin and MMP-14 without interfering 
other protein-trafficking pathways, is nanobodies which are protective molecular chaperones 
in the pathogenic cleavages of variant gelsolin (Van Overbeke et al., 2014, Van Overbeke et 
al., 2015). These nanobodies are futher combined into a single bispecific format so they can 
simultaneously shield variant gelsolin from both proteolytic enzymes. This nanobody based 
approach is adeno-associated virus gene therapy and it has showed promising results in 
gelsolin amyloidosis mice (Verhelle et al., 2017). 
There has been great success in the development of different therapies in TTR amyloidosis; 
the siRNA molecule patisaran (Onpattro) and antisense oligonucleotide inotersen (Tegsedi) 
were approved by FDA in 2018 (Gales, 2019) and the TTR tetramer stabilizer tafamidis 
(Vyndaqel and Vyndamax) in 2019 (Coelho et al., 2016). Unfortunately, this is not the case in 
other amyloidoses. Nevertheless, the same stabilizing strategy, as in tafamidis, could work 
also for AGel formation, if a pharmacologic chaperone or a more specialized kinetic stabilizer 
would be found to stabilize the structure of the G2 domain in variant gelsolin (Solomon et al., 
2012).  
SAP, a widely studied serum protein, plays an important role in clinical diagnostics when used 
in scintigraphy (Hawkins, Pepys, 1995) but it is also a possible drug target for anti-amyloid 
therapy (Pepys et al., 2002). Two drugs have been so far studied for this purpose; miridesap 
to deplete circulating SAP and a humanized monoclonal anti-SAP antibody dezamizumab to 
bind to residual SAP in amyloid deposits, produce unprecedented removal of amyloid from 
the tissues and improve organ function (Pepys, 2018). Miridesap was intended to target SAP 
associated with cerebral Aβ amyloid deposits and cerebral vasculature but it could work also 
in systemic amyloidose, suchs as HGA (Pepys, 2018). 
Interestingly, water soluble poly lactic-co-glycolic acid (PLGA)-encapsulated curcumin and 
emetine nanoparticles seem to be potential modulators of gelsolin amyloidogenesis  
(Srivastava et al., 2015). The curcumin nanoparticles augmented amyloid formation in gelsolin 
by skipping the pre-fibrillar assemblies and increased the fibrillar bulk, while the emetine 
nanoparticles induced non-fibrillar aggregates and were able to defibrillate the pre-formed 
AGel. Despite the functional differences in the aggregates induced by curcumin and emetine 




Aims of the study 
The aims of this study were to characterise the pathological changes of AGel amyloid 
angiopathy in small arteries in more detail, to elucidate pathomechanisms of amyloid related 
elastolysis, and to investigate the effects of variant gelsolin in vascular smooth muscle cells 
from the HGA patients. 
 
The specific aims can be outlined as follows: 
 
• To make a thorough analysis of the pathological changes in the arterial wall in AGel 
amyloid angiopathy (I). 
 
• To characterise the elastolysis in AGel amyloid angiopathy and elucidate the 
pathomechanisms of the amyloid related elastolysis by analysing potential elastases 
from tissue and plasma samples (II). 
 
• To establish VSCM primary cell line cultures from the arteries of HGA patients and 





Materials and methods 
The methods used are summarized in a Table 2. The materials and methods are described in 
detail in the original publications as indicated. 
Table 2. 
Materials and methods Original publication 
Transmission electron microscopy (TEM) 
Stainings  
➢ uranyl acetate and lead citrate 
Examination 
➢ JEM-1400 TEM with Morada TEM CDD camera 
I, II 
Histochemistry 
➢ hematoxylin eosin 




Antibodies used against 
➢ vAGel (rabbit polyconal) 
➢ α-SMA (mouse monoclonal) 
➢ collagen type I (rabbit polyconal) 
➢ collagen type III (rabbit polyconal) 
➢ PINP (rabbit polyconal) 
➢ PIIINP (rabbit polyconal) 
➢ ICTP (rabbit polyconal) 
➢ TGFβ (rabbit polyconal) 
➢ MMP-2 (mouse monoclonal) 
➢ MMP-7 (mouse monoclonal) 
➢ MMP-9 (mouse monoclonal) 
➢ MMP-12 (rabbit polyconal) 
➢ MMP-14 (rabbit polyconal) 
➢ TIMP-1 (mouse monoclonal) 
Other reagents 
➢ biotinylated secondary antibodies 
➢ ABC-reagent 
➢ diaminobenzidine (DAB) 
➢ fluorescent Cy5 secondary antibody 
Examination 
➢ Nikon Eclipse 800 microscope 
➢ Nikon Eclipse Ti-E inverted fluorescence microscope  
I, II 








Generation of primary vascular smooth muscle cell lines 
➢ isolation and culturing of VSMC cells 
III 
Western blotting 
Antibodies used against 






➢ Fluorescent IR 680 secondary antibody 
Examination 
➢ Odyssey Infrared Imaging System 
RNA isolation with commercial kits and sequencing 
➢ total RNA purification kit 
➢ cDNA synthesis kit for qRT-PCR 
➢ cycle sequencing kit 
➢ ABI 3130x1 capillary sequencer 
III 
Cyto- and immunocytochemistry 
Antibodies used against 
➢ gelsolin (mouse monoclonal) 
➢ α-SMA (mouse monoclonal) 
Other reagents 
➢ phalloidin conjugated with fluorescent dye 
➢ fluorescent secondary antibodies 
➢ 4',6-diamidino-2-phenylindole (DAPI) 
➢ 3-amino-9-ethylcarbazole (AEC) 
Examination 
➢ Axioplan 2 fluorescence microscope 
III 
Cell migration analyses  
➢ colorimetric cell migration assay 
➢ scratch assay* 
III 
Chemical stimulation of the cells 
➢ phorbol 12-myristate 13-acetate (PMA)* 
➢ staurosporine treatment 
III 





➢ Shapiro-Wilk test 
➢ student’s t-test 




I, II, III 
Subjects 
➢ Samples included different types of material from  
o 35 patients with HGA  
(17 females and 18 males, mean age 60 years, range 35-86 years) 
o 40 non-HGA-subjects  
(21 females and 19 males, mean age 53 years, range 18-78 years) 
I, II, III 
 






1 AGel amyloid angiopathy 
1.1 Characterization of the HGA patients 
HGA patients of this study were diagnosed with HGA based on the typical clinical triad of 
lattice corneal dystrophy type 2, bilateral progressive facial paresis, and cutis laxa, along with 
family history (first degree relative/relatives with similar symptoms), and/or demonstration 
of the c.640G>A GSN mutation (32 of 35 HGA patients were genetically confirmed). 
Accumulation of amyloid in dermal and vascular tissue samples from HGA patients was 
verified by Congo red stainings and IHC with anti-vAGel antibody. HGA patients showed AGel 
deposition in arterial walls by red-green dichroism under polarized light microscopy in Congo 
red staining, and by immunopositivity for vAGel in IHC staining.  
1.2 Structural changes in arterial walls  
TEM showed clear degeneration and derangement of the arterial wall in the HGA patients. 
This was particularly evident in the tunica media and the lamina elastica interna. The vascular 
smooth muscle layer in the tunica media was disrupted. VSMCs were disorganized leaving 
large areas of extracellular matrix between the cells. Nevertheless, there were similar 
numbers of VSMCs in the patient and control arteries according to the results of anti-α-SMA 
staining.  
1.3 Fibril accumulation 
TEM analysis of both dermal and vascular tissue samples showed massive accumulation of 
fibrils along elastic fibres in all patients with HGA and in none of the controls (Figure 8). Also, 
amyloid fibrils, with a characteristic diameter of 8-10 nm, were detectable in all HGA patients 
throughout the tunica media as focal deposits. In addition to TEM, immunofluorescence 




TEM analysis were observed two types of fibrils: (a) the typical disordered non-branching 
amyloid fibrils and (b) long and parallel-oriented fibrils. The diameter (approximately 10 nm) 
was the same in all fibrils.  
 
 
Figure 8 TEM analysis of the arteries reveals accumulation of fibrils along cutaneous 
elastic fibre which is already severely damaged. (E) elastic fibre, (F) fibrils. 
 
1.4 Changes in collagen type I and III 
We studied the presence, synthesis and degradation of collagen types I and III in arteries as 
they are the most common collagen types in arterial walls (Shekhonin et al., 1985). In a semi-
quantitative observation, the extent of immunopositivity for collagen types I and III was 
increased in HGA patients. Also, their localization in the tunica media was very different from 
that in the controls. Both collagen types were accumulated focally in HGA patients, compared 
to the control subjects, in whom collagens were distributed evenly forming netlike patterns. 
In anti-ICTP staining HGA patients’ tissue samples showed more intense immunopositivity 
compared to the controls suggesting an increase of collagen type I degradation product. 




focally accumulated area. No differences between patient and control groups were noticed in 
the immunopositivity for PINP, PIIINP and IIINTP by semi-quantitative observation. Based on 
immunohistochemistry studies collagen type I and III synthesis and collagen type III 
degradation products were at the same level in both groups. 
2 Elastolysis and potential pathomechanisms 
2.1 Fragmentation of elastic fibers 
In dermal and vascular tissue samples from HGA patients, the elastic fibers, especially the 
lamina elastica interna in arteries, were abnormally fragmented and diminished. This was 
discovered both in Herovici-elastica staining and in TEM (Figure 9). Occasionally, in the HGA 
patients the lamina elastica interna was entirely absent, indicating serious elastolysis and 









Figure 9 TEM analysis of the arteries reveals massive accumulation of fibrils with a 
diameter of approximately 10 nm. Only small remains of the lamina elastica interna 
are left. (F) fibrils, (E) lamina elastica interna and (C) collagen. 
 
2.2 Differences in the elastolysis pattern of elastic fibres 
The degradation pattern of elastic fibres in dermal and vascular tissue samples was alike 
across all HGA patient samples, but differed remarkably from the less prominent age-related 
elastolysis seen in the control samples. Interestingly, it seemed that elastin of the elastic fibres 
was notably decreased or totally lost, whereas fibrils were still present forming a fibrous 
matrix. In the control subjects, the degradation appeared more granular, as in age-related 
elastolysis previously described by Braverman and Pasquali-Ronchetti (Braverman, Fonferko, 
1982, Pasquali-Ronchetti, Baccarani-Contri, 1997) and fibrils were not observed around the 




2.3 Significance of MMPs 
We measured the levels of MMP-2, -7, -9, -12 and -14 in the plasma samples. There was no 
difference in MMP-2, -7, and -12 levels between patient and control groups. In the plasma 
membrane-type MMP-14 could not be detected. However, MMP-9 levels were significantly 
lower in HGA patients vs controls: 0.22 ng/ml (SD 0.10) vs 0.57 ng/ml (SD 0.37), p= 0.002. 
These findings were further confirmed by analysing the IHC stained vascular tissue samples 
semi-quantitatively and quantitatively. In the MMP-9 immunostaining, a typical HGA patient 
had positive area ratio 2.15 times lower than control (mean intensity 2.17 times lower). No 
difference was seen in the IHC stainings for the other MMPs between the patient and control 
groups. 
The previously reported cascade between MMP-9, TIMP-1 (inhibitor of MMP-9) and TGFβ 
(Akhurst, Hata, 2012, Kwak, 2013) led us to study the levels of TIMP-1 and TGFβ as this cascade 
may explain the decreased MMP-9 level in HGA patients. We analysed the vascular IHC 
samples semi-quantitatively and quantitatively and found distinct increase in the TGFβ 
immunoreactivity in a typical HGA patient vs control; positive area ratio 3.40 times higher in 
HGA patient than in control (mean intensity 3.35 times higher). Nevertheless, the level of 
TIMP-1 was identical in both studied groups in the plasma and tissue samples. 
3 Biological effect of variant gelsolin in VSMCs 
3.1 Characterization of vascular smooth muscle cells 
VSMC lines were isolated from the same HGA patients as described in chapter 1.1. All cell lines 
were characterized to be VSMCs by their immunoreactivity to smooth muscle cell actin using 
α-SMA-antibody in cell staining and Western blotting (Figure 10). Prevalence for positive 
staining was nearly 100 % for all VSMC lines, whereas fibroblasts showed negative staining 
with α-SMA-antibody.  
55 
Figure 10 Western blot analysis of fibroblast and vascular smooth muscle cell lines 
using anti-α-SMA-antibody. VSMCs show strong immunopositivity against α-SMA 
whereas fibroblasts are totally negative. 
3.2 Expression of variant gelsolin 
To confirm the expression of variant gelsolin we isolated the mRNA from the cells and 
sequenced the cDNA of three HGA patients (2 VSMC and 1 fibroblast cell lines) and one control 
(VSMC cell line). The sequences showed clearly that cell lines of HGA patients were expressing 
variant gelsolin in a ratio of approximately 1:1, whereas there was no sign of variant gelsolin 
in healthy controls. Yet, the C68 fragment of the gelsolin protein was not detectable in cell 
lysates or culture media of HGA patient cells. This is consistent with previous studies where 
only full-length gelsolin was found in the culture media of human fibroblasts transduced with 
recombinant adenoviruses encoding variant secretory gelsolin and also one HGA patient 
fibroblast cell line (Paunio, T. et al., 1998).  
3.3 Morphology of VSMCs 
In the arteries the morphology of individual VSMCs showed otherwise normal in TEM analysis, 
but often the basal lamina of VSMCs was thickened (Figure 11). The number of VSMCs in 
arteries was also comparable between HGA patients and control subjects. In in vitro studies 
the general morphology of actin cytoskeleton and cytosolic gelsolin distribution were 
evaluated using fluorescent cell stainings (Figure 12). No significant differences in actin 




healthy controls. Both cell types, VSMCs and fibroblasts, grew in an elongated way and formed 
orientated parallel bundles of cells in in vitro culture.  
 
 
Figure 11 In TEM analysis of the arteries the morphology of individual VSMCs showed 
normal, only the basal lamina was often thickened and filled with AGel fibrils. (VSMC) 







Figure 12 Morphology of actin cytoskeleton was evaluated using fluorescent cell 
stainings: phalloidin for actin cytoskeleton (green) and DAPI for nucleus (blue). The 
VSMCs in the image are from HGA patient. Magnification x 400.  
 
3.4 Cell migration, PMA and staurosporine treatments 
Migration of the VSMCs was analysed with a commercial a colorimetric cell migration assay 
(Chemicon International, Billerica, MA) and with a scratch assay (Liang, Park & Guan, 2007). 
The cells showed no notable difference in the migration ability between HGA patients and 
healthy controls.  
Phorbol 12-myristate 13-acetate (PMA), an activator of protein kinase C, treatment was 
performed combined with a scratch migration assay (Figure 13). Cells were incubated 72 hours 
in different concentrations (0 M, 10 nM and 1 µM) of PMA and data was collected at different 





Figure 13 PMA treated cells were studied in a scratch migration assay. This image 
series shows an effect of PMA in different concentrations at time point 24 h in HGA 
patient VSMCs. 
 
Staurosporine, a protein kinase C inhibitor, treatment was also performed. It has the effect of 
rapid disruption of actin microfilaments by inhibiting actin-cytosolic gelsolin induction 
(Miyamoto, Wu, 1990, Yu, Gotlieb, 1992). However, in VSMCs the cell shape did not differ 
between studied groups after treatment. 
3.5 Collagen type I synthesis and degradation in VSMCs 
We performed RIA analyses to evaluate the synthesis and degradation of collagen type I. 
Synthesis (PINP) and degradation (ICTP) of collagen type I was similar between HGA patient 






1 General aspects  
In this study, we have collected several HGA patient and control samples in co-operation with 
plastic surgeons at the Department of Plastic Surgery, Töölö Hospital of Helsinki University 
Hospital during 2010-2014. With this material we were able to perform different histological 
analyses to study new unknown aspects in HGA including the pathology of arteries, elastic 
fibres, collagen and smooth muscle cells. The findings in this study could be relevant even for 
other types amyloid angiopathy. We also have established in vitro cultured vascular smooth 
muscle cell lines. To the best of our knowledge these cell lines are unique in the world. 
The total number of HGA patients in this study is 35 which can be consider rather high in a 
rare disease like HGA. Due to the rarity of the disease we were not able to collect different 
types of samples (tissues for several purposes and plasma) from the same HGA patients in 
order to compare the results from various analyses but on the other hand the results could be 
considered more reliable as the variation of the patient material is wider.  
The research including sample collection from HGA patients and control subjects was 
approved by the ethical committee of HUH. 
2 AGel amyloid angiopathy 
The main findings in our study revealed extensive pathological changes in arteries of HGA 
patients. We observed severe disruption of the arterial wall with disorganization of VSMCs. In 
particular the lamina elastica interna was abnormally fragmented and diminished and VSMCs 
were disorganized leaving large areas of extracellular matrix between the cells in the tunica 
media. The disruption of the arterial wall and loss of elasticity causes very likely more fragile 
arteries with poor mechanical properties and abnormal vascular permeability which may 
contribute to some of the clinical findings and symptoms in HGA. Abnormal fragility has been 
demonstrated earlier clinically in the skin, especially in facial regions (Kiuru-Enari, Keski-Oja & 




connection between cutis laxa and vascular wall vulnerability leading even to aorta ruptures, 
has been recognized in diseases caused by defects in the elastin gene leading to paucity of 
elastic fibres (Szabo et al., 2006). 
The vascular permeability in HGA may cause increased intracutaneous as well as peri- and 
postoperative bleeding risk (Kiuru et al., 2000, Pihlamaa et al., 2011). In Finnish Gelsolin 
Amyloidosis Patient Registry (FIN-GAR) almost 70 % of the HGA patients reported 
intracutaneous, sometimes even very extensive bleedings only after normal physical contact, 
such as hugging or massage (Nikoskinen et al., 2015). Cerebral hemorrhages have also been 
reported, but the risk for those in HGA is not known presently. However, signs of abnormal 
vascular permeability, also in cerebral tissues, were observed in an HGA brain autopsy study 
(Kiuru, Salonen & Haltia, 1999), suggesting increased risk of cerebral hemorrhages. The 
pathological changes in arteries could also allow a better understanding of the characteristic 
neurodegeneration in HGA (Tanskanen et al., 2009), associated with AGel angiopathy in the 
brain, spinal cord, nerve roots and sensory ganglia as shown in previous neuropathological 
studies (Kiuru, Salonen & Haltia, 1999, Kiuru-Enari et al., 2002).  
The loss of elastic fibers and elasticity in vascular walls most probably influences the 
circulation of blood as well by making it more challenging for the entire cardiovascular system. 
This could contribute to the higher consumption of cardiovascular medication in HGA patients 
(Laine et al., 2010). Hypertension is not a common feature in amyloidosis but renal vascular 
amyloidoses, including for example AA and AL amyloidoses, are often accompanied by arterial 
hypertension (Dember, 2006). This should be considered in HGA as well. Besides of the loss of 
elastic fibres, also the deposition of amyloid proteins in the ECM could lead to hypertension 
(Larsson et al., 2006). 
The deposition of AGel fibrils was seen in both vascular and dermal tissues. The massive 
accumulation of fibrils, with a characteristic diameter of approximately 10 nm, was 
surrounding particularly elastic fibres. This finding is consistent with previous studies of other 
types of cutaneous amyloidosis (Winkelmann, Peters & Venencie, 1985, Sepp et al., 1990, 
Vecchietti et al., 2003, Bocquier et al., 2008, Marchand et al., 2013). Nevertheless, the amyloid 
fibril formation and accumulation in arteries does not seem to be severe enough to cause 




Amyloid fibrils and microfibrils of elastic fibres fall into the same diameter range, 
approximately 10 nm (Braverman, Fonferko, 1982, Sipe, Cohen, 2000), which makes 
distinguishing of them very difficult based on the diameter measurement of a single filament 
in TEM. However, other factors like orientation, distribution pattern, and length of fibrils, 
indicate that the fibril matrix in vascular wall and skin of HGA patients was actually comprised 
of at least two different fibril types. Amyloid fibrils are typically disordered non-branching 
fibrils, appearing in oriented parallel forms only when occurring in massive amounts (Cohen, 
Calkins, 1959). Microfibrils of the elastic fibres form loosely packed parallel bundles (Kielty, 
Sherratt & Shuttleworth, 2002) and are well oriented, compared with amyloid fibrils located 
in deposits in ECM at other sites than elastic fibres. There is also a difference in the length of 
the fibrils; amyloid fibrils are only few micrometers long at most (Xue, Homans & Radford, 
2009) while microfibrils can be longer depending on the underlying structures. Based on these 
morphological differences seen in TEM analyses, the fibril deposits along elastic fibers in HGA 
may comprise both amyloid fibrils and elastin-associated microfibrils.  
Collagens have not been studied in HGA before, although findings at clinical examinations 
strongly suggest severe pathological derangement of connective tissues. Abnormal 
consistency and attachment of the skin to underlying tissues together with the difficulties in 
facial and cornea-transplant surgeries are reported (Pihlamaa et al., 2011, Mattila et al., 2015). 
We studied the presence, synthesis and degradation of collagen types I and III in arteries as 
they are the most abundant collagen types in arterial walls (Shekhonin et al., 1985). Our 
results showed that collagen types I and III were atypically focally accumulated in arteries, 
consistent with disruption of the tunica media. In arteries of HGA patients, collagen fibers 
seemed to re-localize to fill the empty space caused by degradation and disorganization of the 
arterial walls whereas in controls collagens were distributed evenly forming netlike patterns. 
Also, the degradation product of collagen type I (ICTP) was increased indicating problems in 





3 Elastolysis and potential pathomechanisms behind it 
Although the vascular system is often affected in systemic amyloidosis very little is known 
about the pathomechanisms in vessels (Kholova, Niessen, 2005). In arteries from HGA patients 
the lamina elastica interna was abnormally fragmented and diminished, sometimes even 
entirely absent, indicating serious elastolysis and causing severe disorganization of the arterial 
wall. Elastolysis in HGA has been described in the cutaneous tissue, particularly in the lower 
reticular dermis, proposed to contribute to cutis laxa (Kiuru-Enari, Keski-Oja & Haltia, 2005). 
These abnormalities typically increase with age and amount of amyloid, though the severity 
of the pathological changes may vary remarkably between patients in the same age group 
(Pihlamaa et al., 2016).  
The elastolysis was very similar in HGA patients between the studied tissue types and between 
individuals, but it varied from the age-related elastolysis seen in control subjects. The main 
difference was the massive accumulation of fibrils surrounding fragmented elastic fibres in 
the samples of HGA patients, as in the control subjects no fibrils were observed. In addition, 
the degradation appeared more granular in control subjects, as shown in age-related 
elastolysis previously (Braverman, Fonferko, 1982, Pasquali-Ronchetti, Baccarani-Contri, 
1997). It seemed that elastin in particular is vulnerable to degradation, whereas the fibrillar 
matrix, consisting of both microfibrils and amyloid fibrils, is resistant to degradation. The same 
phenomenon was present in both dermal and vascular tissues. On the contrary, in degradation 
of elastic fibres in sun-damaged skin microfibrillar structures are lost (Suwabe et al., 1999). 
Our results might indicate that the microenvironment around elastic fibres in HGA favours 
both fibril accumulation and elastolysis.  
The microenvironment around elastic fibres is complex because elastin is surrounded by a 
mantle of microfibrils comprising for example fibrillins, fibulins, emilins and GAGs (Hornebeck, 
Emonard, 2011). Elastases are able to adsorb rapidly onto elastin, but they can also bind onto 
cell surface-associated molecules such as GAGs. GAGs, on the other hand, are known to 
accelerate AGel fibril formation by hastening the fibril extension (Solomon et al., 2011). A high 
amount of GAGs may even permeate elastic fibres both in the skin and the aorta in lysyl 
oxidase (LOX) deficiency related connective tissue disorders (Pasquali-Ronchetti, Baccarani-




normally, also in healthy individuals, associated with elastic fibers (Breathnach et al., 1983), 
may form a nidus for amyloid deposition (Winkelmann, Peters & Venencie, 1985). SAP acts as 
an elastase inhibitor protecting not only normal elastic fibers but also pathological amyloid 
fibrils from proteolytic cleavages (Li, J. J., McAdam, 1984, Suwabe et al., 1999). Despite of the 
hypothetical protection by SAP, in HGA the elastic tissue is destroyed, whereas the AGel fibrils 
resist degradation. The ability of unsaturated fatty acids and heparin(s) to control elastase 
action has been delineated as well (Hornebeck, Emonard, 2011). The crucial factor concerning 
amyloid related elastolysis could be the immobilization and mechanical fatigue of elastin by 
amyloid fibrils which might create a microenvironment that favours elastolysis (Robert, Robert 
& Fulop, 2008, Sherratt, 2009, Hornebeck, Emonard, 2011).   
Interestingly, the fibrous matrix can also include fibrils that are formed of elastin peptides. 
Elastin peptides are known to result from elastase-mediated elastin degradation also in 
normal conditions, such as aging (Baud et al., 2013). These peptides recruit inflammatory cells 
that release their elastases and thereby contribute to the generation of new elastin peptides. 
Their concentration in the blood flow is usually low but can reach high values in aged subjects, 
notably in those developing pathologies, where elastin is massively degraded (Baud et al., 
2013). Unlike insoluble elastin, elastin peptides can modulate the physiology of numerous 
cells, such as fibroblasts, smooth muscle cells, endothelial cells, monocytes/macrophages, and 
lymphocytes (Baud et al., 2013). These bioactive peptides are termed elastokines or elastin-
derived matrikines and they display dual biological functions in pathophysiology: they are 
potent inducers of protease expression catalysing collagenolysis or amplifying elastin 
degradation (Hornebeck, Emonard, 2011). This could be a possible phenomenon aggravating 
elastolysis in HGA as well. It is notable that elastin peptides are also able to form amyloid-like 
fibrils themselves (Bochicchio, Pepe & Tamburro, 2007, Bochicchio et al., 2013).  
Searching for the potential pathomechanisms of elastolysis in HGA, we analysed several 
MMPs known to be capable of degrading insoluble elastic fibres: MMP-2 (72 kDa gelatinase), 
MMP-7 (matrilysin), MMP-9 (92 kDa gelatinase) and MMP-12 (macrophage metalloelastase) 
(Mecham et al., 1997) in tissue and plasma samples from HGA patients and controls. Our 
hypothesis was that AGel accumulation alongside elastic fibers may induce different enzymes, 
like MMPs, attempting to cleave pathological amyloid fibrils but unintentionally cleave elastin 
instead. Furthermore, it has been shown that VSMCs incubated together with medin 




eventually weakens the vessel wall (Peng et al., 2007). We analysed also MMP-14, since it is 
considered to be responsible for the second cleavage of variant gelsolin resulting in the 
amyloidogenic fragments (5 and 8 kDa) (Page et al., 2005). We found that the levels of MMP-
2, -7, -12 and -14 did not differ significantly between HGA patients and control subjects. 
However, MMP-9 levels were significantly lower in HGA patients than in controls. 
Interestingly, this same phenomenon has been reported also in Alzheimer’s disease 
(Horstmann et al., 2010) and in fibrosis in end-stage human heart failure (Polyakova et al., 
2011).  
To understand the lower levels of MMP-9 in HGA patients we studied the previously reported 
cascade between MMP-9, TIMP-1 (inhibitor of MMP-9) and TGFβ (Akhurst, Hata, 2012, Kwak, 
2013). TGFβ, often over-expressed in disease states, upregulates TIMP-1 gene expression 
which results in inhibition of MMP-9 (Akhurst, Hata, 2012, Kwak, 2013). TGFβ can also reduce 
elastin degradation by inhibiting MMP-9 activation by increasing the activities and/or levels 
of TIMP (Alvira et al., 2011). Unfortunately, the lower MMP-9 level was not explained with 
these cascades since the level of TIMP-1, an inhibitor of MMP-9, was not higher in HGA 
patients. However, TGFβ showed increased expression in HGA patients. Interestingly, TGFβ is 
associated with microfibrils, more precisely with fibrillin, in elastic fibres (Sherratt, 2009). 
Microfibrils even control the bioavailability of TGFβ in tissues (Massam-Wu et al., 2010). 
Furthermore, TGFβ is activated by MMP-2 and -9 (Leask, Abraham, 2004). A well-known 
function of TGFβ is to increase collagen synthesis and deposition by fibroblasts, leading to 
fibrosis, but it also promotes a proliferative and/or migratory phenotype of smooth muscle 
cells, which has a negative impact in some vascular diseases (Akhurst, Hata, 2012). TGFβ 
prevents amyloid induced degeneration (Fisichella et al., 2016) but may even contribute to 
the development of cerebrovascular amyloidosis (Weiss, Lifshitz & Frenkel, 2011). Apart from 
beneficial and deleterious roles in amyloidosis, TGFβ in line with HGA contributes to 
amyloidotic corneal lattice dystrophy (Han et al., 2011). In conclusion, TGFβ might play a 
functional role in AGel elastolysis even though fibrosis is not a known consequence in HGA. 
The principal cause for the elastolysis remains to be studied further since the potential 
elastases (MMP-2, -7, -9, -12 and -14) were not shown to be expressed in higher amounts in 
HGA patients as in controls. It is to note that the amount of elastases does not necessarily 




4 Biological effect of variant gelsolin in VSMCs 
We established unique VSCM primary cell lines from the arteries of HGA patients and healthy 
controls to study the biological effect of variant gelsolin. Apart from platelets (Kiuru et al., 
2000) and one fibroblast cell line (Paunio, T. et al., 1998), no other cell types isolated from 
HGA patients have been studied systematically so far. Platelets from HGA patients showed 
altered shape after stimulation with adenosine diphosphate and collagen compared to 
healthy controls (Kiuru et al., 2000). This may indicate that variant cytosolic gelsolin has an 
effect on actin cytoskeleton dynamics. Furthermore, in a neural cell line overexpression of 
gelsolin prevented the formation of actin stress fibers and transfection with variant gelsolin 
induced stabilization of F-actin and reduced plasticity of neural development (Westberg, 
Zhang & Andersson, 1999).  In gelsolin null mice altered actin-cytosolic gelsolin interactions 
were demonstrated as the migration capacity of fibroblasts and neutrophils were reduced 
(Witke et al., 1995) and filopodia retraction was delayed in vitro (Lu et al., 1997). These 
previous results suggest that the variant cytosolic gelsolin and its possible malfunction might 
cause similar alterations in cells of HGA patients, and thereby possibly result in clinical 
symptoms and signs.  
The expression of normal and variant gelsolin was confirmed by analyzing the mRNA sequence 
of HGA patient cell lines. Although both gene alleles were equally expressed in HGA patients 
on mRNA level, cells were not expressing variant gelsolin on protein level in a way that the the 
C68 fragment of the gelsolin would have been detectable. We tried different methods to 
capture the C68 fragment: depletion of albumin from the media samples, use of serum free 
media in cell culture, immunoprecipitation and total protein enrichment to reduce high-
abundance proteins and concentrate low-abundance proteins. The absence of the C68 
fragment could be related to furin activity as well. The artificial environment in in vitro culture 
differs greatly from the natural three-dimensional environment in tissues which is filled with 
compounds and proteins regulating the others. Cells might need for example some signalling 
effect from other cells to support their normal behaviour. However, the absence of the C68 
fragment is consistent with a previous study where only full-length gelsolin was found in the 
culture media of human fibroblasts transduced with recombinant adenoviruses encoding 
variant secretory gelsolin and from one HGA patient fibroblast cell line (Paunio, T. et al., 1998). 




secreted C68 fragment in to culture media. The secretion of C68 might be cell type dependent. 
Overexpression experiments do not necessarily repeat the right conception of the behaviour 
of the cells in normal conditions as detected in patient cells.  
With VSCM primary cell lines we focused to study the actin cytoskeleton organization and 
remodeling. On tissue level, in the arteries the morphology of individual VSMCs was normal 
in TEM analysis, but often the basal lamina of VSMCs was thickened. In cell culture VSMCs 
grew in an elongated way and formed orientated parallel bundles of cells which is the normal 
behaviour for these types of cells. The cells did not show any difference in migration ability 
between the studied groups. No dissimilarities in synthesis (PINP) and degradation (ICTP) of 
collagen type I were observed between HGA patient and control cells. Cells treated with PMA, 
a protein kinase C activator, behaved in the same way, although in a previous study, neural 
cells exposed to PMA responded very differently when variant and wild type gelsolin were 
overexpressed (Westberg, Zhang & Andersson, 1999). Neural cells expressing variant gelsolin 
produced extensive neurite outgrowths whereas cells expressing wild type gelsolin did not. 
The effect of staurosporine, a protein kinase C inhibitor, causing extreme stress  and rapid 
disruption of actin microfilaments by inhibiting actin-cytosolic gelsolin induction (Miyamoto, 
Wu, 1990, Yu, Gotlieb, 1992) was studied too but the cell shape did not differ in VSMCs after 
treatment. As a conclusion, in in vitro studies no significant differences in actin cytoskeleton 
morphology or in cytosolic gelsolin expression were evident, when comparing cells lines from 
HGA patients and healthy controls. This is in line with a previous study which shows that the 
actin-modulating function was not impaired in mouse gelsolin-null fibroblasts transduced with 
variant gelsolin (Kangas et al., 1999). It is, however, quite surprising as gelsolin plays such a 
major role in cell migration and collagen metabolism (Sun et al., 1999, Li, G. H. et al., 2012).  
It would have been very interesting to include cells from homozygous HGA patients in the 
study set to be able to compare possible distinctions of the cells. Yet, in heterozygous cells 
approximately half of the gelsolin, coded with the wild type allele, is functioning normally. On 
the other hand, there are even several other mechanisms that could compensate the possibly 
dysfunctional effect of the variant gelsolin. For example, all six members of gelsolin 
superfamily are known to regulate actin dynamics (Silacci et al., 2004). This is consistent with 
the notion that homozygote HGA patients, in spite earlier and more severe disease 
progression, did not seem to exhibit any unusual symptoms that could be attributed to a loss 




5 Candidates for biomarkers 
Biomarkers are important diagnostic tools for a substantial number of different diseases or 
clinical conditions. They could be helpful also in therapeutic monitoring (Selleck, Senthil & 
Wall, 2017). Biomarkers have been under wide investigation in the researcher community and 
over the past 20 years, there has been an exponential increase in the number of biomarkers. 
Already by 2016 at least 768 259 published articles were directly related to biomarkers (Burke, 
2016). As a comparison there are 896 articles directly related to gelsolin in PubMed to date. 
In HGA biomarkers would be helpful in the surveillance of a progression of the disease. 
Hopefully someday they could play a role in the drug discovery and therapeutic monitoring in 
HGA as well. 
Gelsolin is a multifunctional protein with several activities along the actin homeostasis. Its role 
in a variety of physiological and pathobiological processes has led to the identification of 
gelsolin as a potential biomarker of inflammatory-related diseases. We have studied by large-
scale proteomics a few potential biomarkers for HGA, of both gelsolin - and non-gelsolin based 
nature.  
The following chapters include only unpublished data. 
5.1 Alcohol dehydrogenase 1B 
The proteome analysis was performed for VSMC primary cell lines using two-dimensional 
ultra-performance liquid chromatography with tandem mass spectrometry (2D-UPLC-MS/MS) 
(Waters, Milford, MA, USA) which is a highly sensitive quantitative method for protein 
identification. Relative quantification between samples using precursor ion intensities was 
performed with Progenesis QI for Proteomics software (Nonlinear Dynamics/Waters) and 
ProteinLynx Global Server. Database searches were carried out against UniProtKB/Swiss-Prot. 
This study included VSMC cell lines from 7 HGA patients and 6 control subjects. Interestingly 
we found that alcohol dehydrogenase 1B (ADH1B) was upregulated in HGA patients cell lines 
by 6.7-fold compared to the control subject cell lines. The result was confirmed with Western 
blot analysis using Anti-ADH1B antibody (Thermo Fisher, Waltham, MA, USA) (Figure 14). The 




combined with Image Studio software system (LI-COR, Lincoln, NE, USA). The results were 
impressively similar between two totally different methods as Western analysis showed 
upregulation of 7.4-fold in HGA patient cell lines compared to controls. The cells were also 
stained using the same antibody in immunocytochemistry as in Western blot analysis and it 




Figure 14 Western blot analysis of vascular smooth muscle cell lines using anti-ADH1B 
antibody. VSMCs show clear immunopositivity against ADH1B (green band sized 40 
kDa) in VSMCs from HGA patients. 
 
 
Figure 15 VSMCs of HGA patient were expressing ADH1B (red dots). Nuclei are shown 
in blue (DAPI). Magnification x 400. 
 
The members of alcohol dehydrogenase family metabolize several different substrates, 
including ethanol, retinol, other aliphatic alcohols, hydroxysteroids, and lipid peroxidation 




catabolism. Generally, ADH1B and its different variants are related to alcohol consumption 
and dependence (Hart et al., 2016). For us it is still an open question how ADH1B relates to 
the molecular changes in cells and/or pathomechanisms in HGA. Thus, it would be very 
interesting to study further this protein as a biomarker for HGA. In Alzheimer’s disease 
amyloid β-peptide-binding alcohol dehydrogenase (ABAD) has the capacity to bind amyloid β-
peptide (Du Yan et al., 2000). ABAD belongs to the family of short chain 
dehydrogenase/reductases which have enzymatic activity toward a wide variety of substrates 
including n-isopropanol and β-estradiol. Maybe there is some binding mechanism and 
function also between ADH1B and AGel as has been shown for ABAD and Aβ. 
5.2 C68 fragment in tear fluid 
Another, well-known potential biomarker arises from the abnormal processing of the gelsolin 
protein during the maturation of the misfolded amyloid fragment. To study the gelsolin 
fragmentation in tear fluid we first performed a pilot study with two different kinds of tear 
fluid samples that were collected from a HGA patient; one included local anesthetic and the 
other one was native. Tear fluid was collected in a small capillary tubes and immediately 
frozen at -20°C. The analysis for gelsolin amyloid maturation compounds was performed by 
polyacrylamide gel electroforesis under reducing conditions and Western blot analysis using 
a mouse monoclonal anti-gelsolin antibody (Sigma-Aldrich/Merck, Darmstadt, Germany). As a 
control we used recombinant C68 fragment (Van Overbeke et al., 2014). The result showed 
two separate bands on a gel in the HGA patient tear fluid: consistent with full length gelsolin 
and the C68 fragment. 
The experiment was repeated with two HGA patient and two control subject samples 
following the same protocol. In controls the C68 band was not seen while in HGA patients 






Figure 16 Western blot analysis of tear fluid using anti-gelsolin antibody. In the HGA 
patient the C68 fragment was clearly present whereas in the control subject it is absent. 
 
Tear material for analyses, particularly in HGA where corneal lattice dystrophy plays a major 
role, would be ideal to be used since sample collection is noninvasive and a rather easy 
procedure. Therefore, the analysis of tear fluid and the results as presented here, are 
significant. In addition, tear fluid is much purer and less complex matrix to handle in different 
analyses compared to normal untreated blood (plasma and serum) samples where other high 
abundant proteins, especially albumin, affect the total protein analyses. Albumin 
concentration in tears is 0.023 mg/ml whereas in serum it is 53 mg/ml (Rauz, Saw, 2010). The 
albumin depletion from the blood samples, as usually done in blood-based proteomics 
experiments, does not necessarily solve the problem, because it may reduce also the amount 
and/or number of other proteins, as albumin is a carrier protein that binds to several other 
molecules leading to erroneous depletion of totally unrelated proteins. Considering the high 
sensitivity of the new generation of mass spectrometers we could easily foresee that such a 
technology could be used in the near future for the C68 fragment analysis from a little drop of 







Conclusions and thoughts 
• AGel amyloid angiopathy in HGA results in severe disruption of the arterial walls with 
massive AGel deposition. This may be responsible for several, particularly 
hemorrhagic, disease manifestations in HGA.  
 
• Collagen derangement is consistent with clinical findings of pathological derangement 
of connective tissues. Collagens, in particular their degradation and clearing, are very 
likely linked to other pathological findings such as elastolysis and degeneration of the 
arterial wall. 
 
• The accumulation of fibrils is associated with severe elastolysis. The elastolysis can be 
very striking leading to absence of elastic fibres. The loss of elasticity may cause 
considerable difficulties for HGA patients as the skin and the vascular system loses its 
functionality. The elastolysis could also appear in other organs as well which may have 
clinical significance in HGA. 
 
• The fibrillar matrix is massive in HGA patients, especially surrounding elastic fibres like 
lamina elastica interna. This fibrillar matrix could consist of different kinds of fibrils: 
AGel amyloid fibrils, microfibrils of elastic fibres, and also amyloid-like fibrils consisting 
of elastin peptides.  
 
• The microenvironment on elastic fibres seems to favour fibril accumulation and elastin 
degradation in HGA and in other reported amyloidoses with elastolysis. These 
microenvironmental changes could be differences in molecular conditions, for 
example presence of SAP and GAGs, but also the fibrils might accelerate fibril 
formation themselves. For example, the immobilization and mechanical fatigue of 
elastin by amyloid fibrils could influence fibril formation and accumulation.  
 
• MMP-9 is decreased and TGFβ is increased in HGA patients. Reasons for these changes 




disease with deposition of Aβ as well. There may be a regulating cascade existing that 
is involved in amyloid formation and existence at least in some amyloidoses. 
 
• The unaltered cytoskeletal actin-gelsolin interactions in studied cells imply that HGA 
results rather from a toxic-gain-of-function than loss-of-function mechanism.  
 
• Two potential biomarkers, alcohol dehydrogenase 1B (ADH1B) and the C68 fragment 
of variant gelsolin demonstrated in tear fluid of HGA patients, might be useful tools in 
evaluation of the progression of HGA in patient. They could possibly even aid in the 
follow-up of future specific treatment approaches. 
 
• Amyloid angiopathy with severe elastolysis as observed in HGA, may have clinical 
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